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ABSTRACT OF THE DISSERTATION
Identification and Characterization of the C/s-acting Elements
around the Murine CD4 Enhancer
by
Xin Dong
Doctor of Philosophy, Graduate Program in Biochemistry
Loma Linda University, September, 2000
Dr. R. Bruce Wilcox, Chairperson

The cluster determinant 4 (CD4) molecule is a transmembrane
glycoprotein. CD4 is essential for normal T helper cell function and plays an
important role in T cell development and activation. CD4 is encoded by a single
gene located on chromosome 6 in the mouse and chromosome 12 in the human.
Both human and murine CD4 genes are divided into ten exons spanning more
than 25 kb and have a large non-coding region in the first and third intron. CD4
gene expression is controlled primarily at the transcriptional level during T cell
development and activation.
An enhancer has been identified approximately 13 kb 5' of the
transcriptional start site of the murine CD4 gene. A comparison of the DNA
regions around and within the mouse CD4 enhancer with that of the human CD4
enhancer region reveals 11 regions of homology. There is also a DNase I
hypersensitive (DH) site located immediately upstream of the 5' enhancer.
These data suggest that the enhancer may be a part of a larger control element
xix

of deletions (31 and 5' direction) covering a 1158 bp region containing the
enhancer and the 5' DH site were engineered using the Bal 31 deletion method
and then analyzed using the transient transfection, chloramphenicol
acetyltransferase (CAT) assay. Two novel c/s-acting elements with silencer
function were discovered by Bal 31 deletions. Their silencer functions were
further confirmed by subcloning them at different positions and different
orientations relative to CD4 promoter. These subcloned constructs were tested
for function in transient transfection and CAT assays. Furthermore these two
c/s-acting elements were also analyzed with the electrophoretic mobility shift
assay for their ability to bind cell-specific nuclear proteins. In addition, the
potential binding sites for transcriptional factors within these novel c/s-acting
elements were identified by the DNase I footprinting technique.
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CHAPTER ONE
I. Introduction
The T cell is an important controlling cell type in the maintenance of the
vertebrate immune response (Hedrick, 1989). Two different functional
subclasses of T cells, the cytotoxic T (Tc) cell and the helper T (Th) cell, play
important roles in the immune response. The Tc cell kills virally infected cells
and tumor cells, while the Th cell secretes protein factors that regulate the
immune response. Most Th cells express the cluster determinant 4 (CD4)
molecule and recognize antigen bound to major histocompatability complex
(MHC) class II molecules, whereas most Tc cells express the cluster determinant
8 (CDS) molecule and recognize antigen bound to MHC class I molecules
(Janeway, 1991).
CD4 is essential for the normal function of Th cells and plays an important
role in T cell development and activation (Fames, 1989; Janeway, 1991; Julius
et al., 1993).

A.

CD4 STRUCTURE AND FUNCTION
1.

Polypeptide Structure

The CD4 molecule on the cell surface was first identified by use of the
W3/25 monoclonal antibody (mAb) in the rat (Williams et al., 1977). The human
homologue of the W3/25 antigen was identified with the mAb T4 (Reinherz et al.
1979) and later termed CD4. The CD (cluster determinant) nomenclature was
introduced to group mAbs that recognized the same antigen at the surface of

1

human leukocytes (Littman, 1996). The CD4 molecule is a membrane
glycoprotein of approximately 55 kDa, which immunoprecipitates as a single
polypeptide chain (Classon et al., 1986; Dialynas et al., 1983). The CD4
consists of four external domains, a hydrophobic transmembrane domain, and a
cytoplasmic tail (Littman and Gettner, 1987; Maddon et al., 1985) (Fig. 1.1). The
X-ray crystallography structures of the four extracellular domains of CD4
indicated that these domains were members of the Ig (immunoglobulin)
superfamily (Williams and Barclay, 1988). Domains 1 and 3 are similar to
antibody variable region (V-set) domains, while domains 2 and 4 are closer to
the size of C-domains but with patches of sequence similar to V-domains and
this group is termed C2-set domains (Williams and Barclay, 1988).
Amino acid sequence comparisons of CD4 from a number of species
demonstrate strong conservation within all domains of CD4 (Littman, 1987) (Fig.
1.2). The mature CD4 polypeptide chain is preceded by a 23- or 26-amino acid
signal peptide in humans and in mice, respectively. The extracellular portion of
CD4 consists of 374 amino acids in humans and 368 amino acids in mice. This
is followed by a transmembrane segment (26 amino acids in humans, 25 in
mice) and a cytoplasmic tail (38 amino acids in both species). There is species
variation in CD4 N-linked glycosylation with only one site in rabbit CD4, two in
human CD4, three in rat and mouse CD4, four in chimpanzee CD4 (Fomsgaard
et al., 1992).

2

Figure 1.1. Diagram of CD4 structure. The CD4 consists of four external
domains, a hydrophobic transmembrane domain, and a cytoplasmic tail.
Domains 1 and 3 are similar to antibody variable region (V-set) domains, while
domains 2 and 4 are closer to the size of C-domains but with patches of
sequence similar to V-domains and this group is termed C2-set domains. S-S
indicates the disulphide bridge between the (3 sheets. (Adapted from Littman,
1996).

3
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Figure 1.2. Alignment of the sequences of the extracellular regions of CD4 from
human, rat, mouse, cat, dog and rabbit. (Adapted from Littman, 1996)
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Each CD4 molecule of the five species listed has six cysteine residues external
to the cell, which are conserved between species and form three intrachain
disulfide loops connecting adjacent cysteines (Classon et al., 1986). The
cytoplasmic tail is the most highly conserved domain of CD4 between mouse
and other species, with 80% identical residues in human, 98% identical residues
in rat. The strong conservation in the cytoplasmic domain of CD4 suggests that
it is essential for the function of the molecule. There is much greater divergence
in the other domains, with overall homologies of 55% between human and
mouse and 74% between rat and mouse (Littman, 1987).
2.

Chromosomal Location

CD4 is encoded by a single gene on the chromosome 6 in the mouse
(Field et al., 1987) and chromosome 12 in the human (Isobe et al., 1986; Kozbor
et al., 1986). This region of chromosome 12 shows striking homology to the
distal segment of mouse chromosome 6. CD4 is located in a synentic group that
contains a number of different genes that play important roles in the function of
the immune system. These genes include LAG-3 (Triebel et al., 1990), CD27
(loenen et al., 1992), TNFR, FGF-6, KRAS-2 (Elliott and Moore, 1992) , and HCP
(Yi et al., 1992a; Yi et al., 1992b). The organization of these genes to the same
chromosomal locus may be important in controlling their expression.
3.

Gene Structure

The cDNAs for the CD4 gene have been cloned from man (Maddon et al.
1985), mouse (Tourvieille et al., 1986), chimpanzee, African green monkey,
sooty mangabeys, patas monkey, rhesus monkey, pig tail macaque (Fomsgaard
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et al., 1992), cat (Dumont-Drieux et al., 1992; Norimine et al., 1992), rabbit
(Hague et al., 1992), dog (Milde et al., 1993), miniature swine (Gustafsson et al.
1993), and rat (Clark et al., 1987). Furthermore, the genomic organization of the
murine and human CD4 genes have been determined (Gorman et al., 1987;
Littman and Gettner, 1987; Maddon et al., 1987; Blum et al., 1993). Both genes
are divided into ten exons and nine introns. The mouse CD4 gene spans about
26 kb and has a large non-coding region in the first intron (6.4 kb) and third
intron (8.6 kb). The human CD4 gene spans about 33 kb and also has a large
first and third intron (Maddon et al., 1987). Rearrangement of the CD4 gene is
not required for the expression (Maddon et al., 1985). Numerous T cell- and
non-T cell-specific DNase I hypersensitive (DH) sites were mapped within both
introns (Maddon et al., 1987; Sands and Nikolic, 1992; Siu et al., 1994).
Therefore, it is suggested that these two large introns may be involved in
regulation of CD4 gene expression in different tissues.
Crystallographic studies indicate that CD4 exists as a rod-like structure of
about 125 angstroms in length and 25 to 30 angstroms in width (Ryu et al., 1990;
Wang et al., 1990; Harrison et al., 1992; Capon and Ward, 1991), whereas the
height of a class II MHC molecule is about 73 angstroms (Brown et al., 1993)
and that of the TCR may be 60-70 angstroms (considering that both the a and
the (3 chains consist of two immunoglobulin-like domains). Therefore, the D3
and D4 domains of CD4 would be unlikely to reach beyond the TCR to contact
class II MHC molecules. If so, how can mutations in D3 and D4 affect CD4
function? One possibility is that the mutations may induce structural changes in
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distant regions of CD4, indirectly disturbing interactions with class II MHC and/or
TCR/CD3 complexes (Fleury et al., 1991). Alternatively, the signaling function of
CD4 may depend on protein-protein interactions, either between CD4 molecules
or between CD4 and TCR/CD3 components, and this may involve the
membrane-proximal D3 and D4 domains (Vignali et al., 1993).
4.

Functions

Unlike B cells, which secrete immunoglobulin that can recognize soluble
antigen, T cells require presentation of the antigen by a specialized antigenpresenting cell (ARC).

In this process the ARC engulfs the antigen, degrades it

into small peptide fragments, and presents the peptides on its cell surface bound
to a molecule encoded by the major histocompatibility complex (MHC) (Fig 1.3).
The T-cell antigen receptor (TCR) recognizes a combination of both the antigenic
peptide and the MHC molecule. Ligation of the TCR then leads to the activation
and maturation of the T cell. As mentioned before there are two major classes of
T cells: Tc recognize and kill virally infected self cells, whereas Th release
cytokines that stimulate the other cell types in the immune system. Most Tc cells
only recognize an antigen when it is bound to one type of MHC molecule,
referred to as the MHC class I molecule (Doyle and Strominger, 1987; Julius et
al., 1993). Conversely, most Th cells only recognize an antigen when it is bound
to the second major class of MHC molecules, the class II molecule (Doyle and
Strominger, 1987; Julius et al., 1993). This class specificity is enhanced by the
T-cell-subclass-specific co-receptor molecules (CD4 and CDS) that bind to and
distinguish between class I and class II molecules.
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The CD4 acting as a co-receptor molecule specifically recognizes MHC class II
molecules, whereas CDS recognizes MHC class I molecules. The interaction of
the co-receptor with MHC serves both to increase the avidity of the T cell for the
ARC and to send additional stimulatory signals to the T cell via an interaction
with the tyrosine kinase p56lck (also called Lck).
a.

Co-receptor Function

Originally, the role of the CD4 in the activation of T lymphocytes was
indicated when anti-CD4 antibodies inhibited a variety of T lymphocyte effector
functions in vitro (Krensky et al., 1982; Spits et al., 1982; Wilde et al., 1983;
Rogozinski et al., 1984). In addition, anti-CD4 antibodies inhibited cytolysis of
target cells by preventing conjugate formation, suggesting that CD4 may play a
role in T cell adhesion (Biddison et al., 1984). The ability of anti-CD4 antibodies
to inhibit conjugate formation was inversely related to the avidity of the T
cell/APC interaction (Biddison et al., 1984), suggesting that, when the avidity of
the T cell receptor (TCR) for antigen/MHC is low, the CD4:MHC class II
interaction may become critical. It was later demonstrated that physical binding
exists between CD4 and the non-polymorphic regions of MHC class II molecules
(Doyle and Strominger, 1987; Gay et al., 1987; Sleckman et al., 1987). The
specificity of this binding was confirmed by its complete inhibition by either antiCD4 mAb or a mixture of anti-class II mAbs. This study further indicates that the
interaction between CD4 and class II can take place in the absence of the TCR.
Gay et al. (1987) have drawn similar conclusions concerning the ability of human
CD4 to enhance responsiveness in the presence of class II MHC molecules
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using another xenogeneic system. Their results indicate that CD4 interacts with
class II MHC molecules and that this interaction enhances T cells. Similar
conclusions regarding the function of mouse CD4 have been obtained in a totally
syngeneic system (Gay et al., 1987). To explain the strict association of CD4
expression with class II restriction, the co-receptor model was proposed for CD4
function (Janeway et al., 1989). This model postulates that, aside from any
adhesive function, CD4 plays a critical role as a component of the TCR complex
required for efficient and proper antigen-dependent signal transduction.
Furthermore, site-directed mutagenesis and gene transfer techniques have
yielded a substantial understanding of the molecular basis for CD4-MHC class II
molecule interactions. The atomic resolution of the three-dimensional structure
of crystals consisting of the two NH2-terminal domains (D1 and D2) of CD4
made it possible to relate the results of mutational analyses to the strucutre of
CD4 (Ryu et al., 1990; Wang et al., 1990). These mutational analyses have
identified multiple regions of CD4 that either directly affect binding to class II
MHC molecule or downstream functions dependent on interaction with class II
molecules. An extended region of functional significance is formed on one side
of domain 1 by residues in the A-strand, the A/B loop, the B-strand, the
beginning of the CDR1-like B/C loop, the CDR3-like F/G loop, and the D-strand
as well as residues in the D/E-loop and at the end of the E-strand (Clayton et al.
1989; Moebius et al., 1993). On the same side of CD4, residues in the A-strand
and the A/B and B/C-loops of domain 2 also contribute to function. These data
imply the existence of two extended regions located on two spatially discrete
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faces of CD4 molecule that are involved in MHC class-ll dependent CD4
function.
b.

Interaction of CD4 with the T Cell Receptor/CD3 Complex

A number of observations suggest that CD4 associates with the TCR/CD3
complex during T cell activation and that this association may be critical for CD4
mediated enhancement of T lymphocyte responsiveness. CD4 redistributes with
the TCR/CD3 complex to the site of contact between the T cell and an ARC
bearing specific antigen (antigen which binds the TCR) but does not redistribute
to the site of contact with an APC-bearing nonspecific antigen (Kupfer et al.
1987). This indicates that CD4 redistribution is dependent on TCR recognition.
CD4 can be induced to co-modulate with the TCR following stimulation with
anti-TCR antibodies (Saizawa et al., 1987); similarly, anti-TCR antibodies can
induce CD4 to co-cap with the TCR/CD3 complex under activating conditions
(Rojo et al., 1989). Interestingly, the ability of anti-TCR antibodies to cause CD4
co-capping correlates with the efficiency of antibody mediated activation of the T
lymphocyte (Portoles et al., 1989; Rojo et al., 1989; Dianzani et al., 1992).
Anti-TCR antibodies which induce CD4 co-capping with the TCR/CD3 complex
also cause phosphorylation of the TCR-£ chain much better than antibodies
which do not induce CD4 co-capping (Dianzani et al., 1992). These data suggest
that the coassociation of CD4 with the TCR/CD3 complex has important
consequences for T cell activation.
In contrast to immunoglobulins that recognize a wide diversity of ligand
structure, T cells participate in adaptive immune responses by recognizing short
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peptides bound to a common framework consisting of the surrounding MHC
class I or class II molecule (Germain, 1994). A TCR must discriminate among
thousands of subtly different peptides bound to identical MHC molecules
expressed on a single cell surface. High affinity receptors discriminate well
between diverse structures, but poorly between related structures. Due to this
feature of receptor-ligand interactions, TCR cannot be of very high affinity, as
this would reduce their specificity of recognition and their ability to distinguish
between MHC molecules occupied with peptides of similar structure (Weber et
al., 1992). Although modest TCR affinity aids in discriminatory recognition of
similar peptide-MHC molecule complexes, this feature also limits the sensitivity
of the response system. But the T cell activation system must be very sensitive
to ensure effector responses at the low concentrations of antigen available early
after infection. The co-receptor system is the solution to the problem of
maintaining high sensitivity and specificity in the T cell recognition of peptideMHC complexes. In effect, the CD4 co-receptor is an integral part of the TCR
recognition unit, which allows high specificity as the TCR scans through the
many potential MHC ligands on a cell surface. At the same time, the affinity of
the receptor alone for MHC molecules is very low, preventing interactions in the
absence of TCR recognition (Gay et al., 1987; Janeway, 1992). Once such
specific recognition takes place, the ability of CD4 to simultaneously engage the
recognized peptide-MHC molecule and the attached TCR complex results in
both a stabilization of co-receptor-MHC molecule binding and a major increase in
the effective affinity of the TCR. By occuring after the initial interaction of a TCR
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with a suitable peptide-MHC complex, this affinity increase can happen without a
loss of specificity. This sequential, cooperative mechanism permits low numbers
of specific ligands on a cell surface to activate the TCR signal transduction
machinery to stimulatory levels (Demotz et al., 1990; Harding and Unanue,

1990).
c.

CD4 and Signal Transduction

CD4 is not merely an adhesion or accessory molecule, but also
contributes to T cell activation by acting as a co-receptor that helps form a multi
protein signaling assembly with the TCR and CD3/^ complex (Janeway, 1992;
Julius et al., 1993). The co-receptor contributes to intracellular messenger
generation by participating in antigen recognition and receptor clustering and
through its noncovalent association with the protein tyrosine kinase p56lck (Rudd

et al., 1989; Veillette et al., 1989).
1).

Interaction of CD4 and p56lck

The idea that CD4 plays a role in signal transduction, as well as
ligand-binding capabilities, was first supported with the finding that the
cytoplasmic tail of CD4 is linked noncovalently with the amino-terminal domain of
the p56lck protein tyrosine kinase, a member of the Src family (Rudd et al., 1988;

Veillette et al., 1988; Shaw et al., 1989; Bolen et al., 1991). In addition
Cross-linking of CD4 with monoclonal antibodies (mAbs) results in a rapid
increase in the phosphorylation of p56lck on both tyrosine and serine residues, an
increase in p56lck activity (Marth et al., 1989; Luo and Sefton 1990) and an
increase in tyrosine phosphorylation of a number of cellular proteins (Veillette et
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al., 1989). These data suggested that CD4 plays an important role in the
activation of the p56lck.
p56lck, also called Lck, is a 56 kDa protein composed of a unique
NH2-terminal domain, a Src-homology 2 (SH2) domain, a Src-homology 3 (SH3)
domain and a kinase domain (Ravichandran et al., 1996). The CD4-p56 lck
interaction occurs between the cytoplasmic domain of CD4 and the NH2-terminal
domain of p56lck (Shaw et al., 1989; Vega et al., 1990; Veilletre et al., 1990).
Site-directed mutagenesis has established that two closely positioned cysteine
residues in the cytoplasmic tail of CD4 (positions 420 and 422) and two
cysteines in the NH2 terminus of p56lck (positions 20 and 23) are essential for this
CD4-p56lck interaction (Shaw et al., 1990). The expression of CD4 point
mutants, in which the cysteines necessary for interaction with p56lck were
mutated, did not enhance antigen responsiveness (Glaichenhaus et al., 1991;
Collins et al., 1992). Interestingly, these CD4 mutants also failed to co-associate
with the TCR/CD3 complex during T cell stimulation (Collins et al., 1992). Since
IL-2 production in response to cross-linking with anti-TCR and anti-CD4
antibodies was also diminished (Collins et al., 1992), these data suggest that the
loss in CD4 enhancement of antigen responsiveness is due largely to a lack of
CD4/p56lck mediated signaling. Therefore, the CD4/p56lck association is
necessary for co-receptor function via CD4.
The evidence that CD4 binds both MHC class II molecules and p56 lck
suggests that CD4 fulfills its requirements as a co-receptor by participating in the
activation or differentiation of the cell through intracellular signaling. Models in
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which CD4 acts by modulating the protein kinase activity of p56lck (Shaw et al.
1989) and by bringing p56lck into the antigen receptor complex at the time of
antigen recognition (Weiss et al., 1993; Veillette and Davidson, 1992b) have
been proposed. Although CD4-p56lck association is essential for CD4 coreceptor
activity, the tyrosine kinase activity of CD4-associated p56lck appears to be
dispensable for CD4 function. Models in which CD4 potentiates TCR signaling
both by modulating the protein kinase activity of p56lck(Luo et al., 1990) and by
recruiting the activated P56lck molecules in the vicinity of the antigen receptor
complex have been proposed (Veillette and Davidson, 1992). The recruited
p56lckthen enhances TCR signals by phosphorylating rate-limiting substrates
such as CD3/^ and Zap-70. In addition, studies performed using chimeric CD4p56lck molecules demonstrated that the CD4-associated p56lck improves TCR
signaling by a mechanism unrelated to its tyrosine protein kinase activity but
relying on its SH2 sequence (Xu and Littman, 1993). However, studies
performed using chimeric CD4-p56lck molecules demonstrated that the catalytic
activity of p56lck is not required for co-receptor function (Xu and Littman, 1993).
p56lck is required to functionally couple the TCR to signal transduction (Abraham
et al., 1991a, b; Weiss et al., 1993; Haughn et al., 1992). Therefore, p56 Ick
appears to have two distinct functions in co-receptor-assisted T cell activation.
One of these functions, which may occur either with or without the co-receptor,
involves localization of enzymatically active p56lck in close proximity to the TCR
complex, where it acts early in the signaling pathway (Anderson et al., 1994).
The second function of p56lck is to coordinate interaction of the TCR and co-
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receptor with a single MHC molecule, possibly by helping to stabilize CD4 in the
antigen receptor complex in a kinase-independent fashion (Saizawa, 1987;
Collins, 1992). While evidence indicates that both CD4 and p56lck are critical
components of early T cell differentiation, they do not appear to require
association with each other (Killeen and Littman, 1993). Instead, p56lck may
mediate signaling from the TCR ^ chain and initiate allelic exclusion, expansion,
and maturation of immature thymocytes. The transmembrane and/or
cytoplasmic domain of CD4 may signal via other proteins (Anderson et al., 1994;
Julius et al., 1993).
CD4 appears to have a number of other functions as well. Cross-linking
of CD4 has been reported to result in increases in the production of inositol
phosphates (Ledbetter et al., 1988), in Ca2+ flux (Kanner et al., 1992), and in Fas
antigen expression (Oyaizu et al., 1994). Cross-linking of CD4 results in tyrosine
phosphorylation of a number of substrates, such as the ^ chain (Veillette et al.,
1989b) and p56lck (Veillette et al., 1989b). CD4 cross-linking also results in an
increased activity of the associated p56lck (Veillette et al., 1989a, 1991; Luo and
Sefton, 1990). In addition, CD4 cross-linking contributes to IL-2 down-regulation
(Tamura et al., 1990; Takahashi et al., 1992; Corado et al., 1991; Ledbetter et
al., 1988) partially by inhibiting the binding activities of nuclear factors involved in
IL-2 transcription (Jabado et al., 1994). Finally, CD4 either binds or associates
with a complex of proteins that bind an interleukin secreted by CD8+ T cells
called lymphocyte chemoattractant factor (LCF). The interaction of LCF with
CD4 stimulates migration of CD4+ lymphocytes, monocytes, and eosinophils, and
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stimulates the growth of CD4+ T cells (Center et al., 1995; Cruikshank et al.
1994).

B.

DEVELOPMENTAL BIOLOGY OF T CELLS
1.

T Cell Progenitors

Lymphoid cells derive from hematopoietic stem cell (HSC) in the fetal liver
and then in the bone marrow of the adult (Shortman and Wu, 1996). The HSC
phenotype has been defined by the presence of the surface markers: Sca-1 +
(Ly-6A); CD117+ (stem-cell factor receptor, c-kit); CD44+(Pgp-l); Thy-110; HSA'/+
(heat-stable antigen), and is negative for all lineage markers (Lin')(Shortman et
al., 1996; Spangrude et al., 1988; WeissmanIL et al., 1994). The stem cell
population appears to be separable into subpopulations representing stages of
differentiation between the most primitive long-term reconstituting cells and the
lineage-committed progenitors (Uchida et al., 1992).
It was originally observed that a pool of thymocytes lacking high-level
expression of CD4, CDS and CDS contained precursors capable of reconstituting
thymic development after adoptive transfer (Fowlkes et al., 1985). Then a
subset of CD4' CDS' CDS' (triple negative) thymocytes was identified to give rise
to all other thymocyte subsets (Wu et al., 1991a; Ardavin et al., 1993; Antica et
al., 1993). It was suggested that subset of triple negative thymocytes contained
the earliest progenitor cells (Shortman et al., 1996). Interestingly, these
progenitors from adult mice characteristically express low, but detectable, levels
of CD4 (termed “CD4l0 progenitors”), whereas the earliest progenitors from fetal
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mice do not express CD4 (Shortman et al., 1996; Antica et al., 1993).
Importantly, both fetal and adult progenitors can give rise to lymphoid cells other
than T cells, which is why they were termed thymic lymphoid progenitors (TLPs)
(Ardavin et al., 1993).
The surface phenotype of TLPs includes the strong expression of the
putative thymic homing receptor CD44. TLPs also express CD117 and the IL-7
receptor, which together promote thymocyte survival and growth (Zlotnik et al.
1995; Godfrey et al., 1994; Moore et al., 1995; Hozumi et al.,1994; Matsuzaki et
al., 1993; Rodewald et al., 1995; Peschon et al., 1994; Von Freeden-Jeffry et al.,
1995). In addition, TLPs lack markers such as CD25 (IL-2 receptor a chain) and
express low levels of Thy-1 and HSA (Shortman et al., 1996). Thymic lymphoid
progenitors are the most immature thymocytes known and are not yet committed
exclusively to the T-cell lineage.
2.

Thymic Development

a.

Early Thymic Differentiation

The TLPs travel to the thymus via the blood circulation (Kimoto et al.
1993; Peault et al., 1994). The first major event in the thymic development of T
cells occurs when TLPs seed the thymus. Differentiation to a T-cell phenotype
depends on interactions of hematopoietic precursors with thymic stroma cells
derived from the third pharyngeal cleft (Owen and Jenkinson, 1984). Both
epithelial and mesenchymal cells from the stroma are necessary for T cell
development in the thymums (Anderson et al., 1993). The architectural
organization of the thymus dictates that early differentiation occurs in the cortical
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circumference of the thymic lobe (Boyd et al., 1993). Early thymopoiesis
involves signals for survival as well as signals for differentiation. If differentiation
is blocked, the later stages are lost and the early progenitors remain limited by
programmed cell death (Zoeiga-pfycker and Lenardo, 1996).
Each stage of early thymocyte differentiation is characterized by cellular,
molecular and genetic distinctions which are described more fully below (Fig.
1.4).
1)-

Pro-T cells

These cells continue to express CD44 and CD117, but now express CD25
and other “activation” markers (Shortman et al., 1996; Zlotnik et al., 1995;
Godfrey et al., 1993). Commitment to the T lineage and proliferation takes effect
at this stage (Moore et al., 1995; Penit et al., 1995), but TCP rearrangement has
not yet been initiated.
One of the first events that takes place within about a day of thymic entry
is the induction of CD25 expression (Amagai et al., 1995). Expression of CD25
on thymocytes that are CD 1177CD447Thy-1l0 defines the pro-T cell stage
(Godfrey et al., 1993; Zae-iga-PflYcker et al., 1995; Moore et al., 1995), and
coincides with the acquisition of an “activated” cell phenotype (Rothenberg et al.
1992).
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Several characteristics of antigen-activated mature T lymphocytes, including the
induction of gene regulatory proteins such as NF-kB, NF-AT and AP-1, as well
as surface markers such as CD25, CD54 (ICAM-1) and CD59 (Ly 6A), appear at
this stage (Zae-iga-PflYcker et al., 1993; Chen et al.,1993). The TCR-(3 and
TCR-y genes retain their germline configuration (Dudley et al., 1994; Hozumi et
al.,1994; Godfrey et al., 1994). In mature T cells, TCR stimulation is required for
an activation response, but in early pro-T cells, the “activated” phenotype occurs
before TCR gene rearrangement or expression (Rothenberg et al., 1992;
Rothenberg er al., 1991). This has led to the hypothesis that the pro-T-cell stage
includes a TCR-independent activation event (Zae-iga-PflYcker et al., 1993;
Rothenberg et al., 1992; Chen et al.,1993).
2).

Early pre-T cells.

These cells no longer express stem-cell markers such as CD44 and
CD117, but continue to express CD25 (Godfrey et al., 1993; Godfrey et al.
1993; Pearse et al., 1989). TCR (3 gene rearrangement and expression of the
pre-T a gene are initiated (Dudley et al., 1994; Hozumi et al.,1994; Godfrey et
al., 1994; Saint-Ruf et al., 1994 ).
The loss of CD44 and CD 117 expression together with the expression of
high levels of CD25, Thy-1, HSA and Sea-1/2 characterizes the early pre-T-cell
stage (Shortman et al., 1996; Zlotnik et al., 1995). Early pre-T cells appear to
have a lifespan of only three days, and about 70% of these do not progress to
the late pre-T-cell stage(Penit et al., 1995). Concomitant with the transition from
a pro-T-cell to an early pre-T-cell phenotype is a transient slowdown in
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proliferation as TCR-p gene rearrangement is initiated (Penit et al., 1995; Dudley
et al., 1994; Hozumi et al.,1994; Godfrey et al., 1994). TCR-P gene
rearrangement occurs before TCR-a gene rearrangement and is necessary for
further thymocyte maturation (Groettrup et al., 1993; Mombaerts et al., 1992). In
TCR-p deficient mice, thymocyte development remains suspended for the most
part at the pre-T-cell stage, but TCR-a gene rearrangement and inefficient
progression to the DP stage still occur (Mombaerts et al., 1992). Synthesis of
the TCR-p protein, in addition to being essential for thymocyte maturation, also
promotes allelic exclusion (Shortman et al., 1996).
The molecular characterization of a pre-TCR complex has provided a
fundamental insight into regulation at the pre-T-cell stage. The pre-TCR is an 80
kDa protein complex that consists of the TCR-p protein covalently linked by a
disulfide bond to a 33 kDa glycoprotein (gp33), termed “pre-Ta” (Saint-Ruf et al.
1994; Groettrup et al., 1993). Pre-Ta is a transmembrane protein that shares
homology with TCR chains but contains only a single extracellular
immunoglobulin-like structural domain (Saint-Ruf et al., 1994 ). The
intracytoplasmic portion of the pre-Ta chain is longer than that of TCR chains
and contains potential signalling motifs (Saint-Ruf et al., 1994). Expression of
the pre-Ta gene is initiated at the pro-T-cell stage and continues up to the late
pre-T-cell stage.
The pre-TCR appears to work as a surface receptor that employs both
CD3e and the p56lck tyrosine kinase to transduce the selective signal (Levelt et
al., 1995a; Levelt et al., 1995b). Gene deficiencies for pre-Ta, CDS e, and p56 Ick
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or the presence of a dominant-negative version of p56lck(kinase- negative), all
arrest differentiation between the early and late pre-T-cell stages, leaving
significant numbers of CD44' CD25+ thymocytes, but reduced or absent CD44'
CD25' thymocytes (Fehling et al., 1995; Renard et al., 1995; Malissen et al.
1995; Anderson et al., 1995; Molina et al., 1992; Levin et al., 1993). The origin
of the pre-TCR selective signal remains unknown.
3).

Late pre-T cells.

At this stage, thymocytes lose CD25 expression as successful TCR-(3
chain rearrangement and expression are accomplished (Dudley et al., 1994;
Hozumi et al.,1994; Godfrey et al., 1994). Dimers formed from the (3 chain and
the non-polymorphic pre-T a chain provide a signal for maturation to the
CD47CD8+ stage (Saint-Ruf et al., 1994; Groettrup et al., 1993; Fehling et al.
1995).
The late pre-T-cell stage is marked by the loss of CD25 expression and
the onset of renewed proliferation, resulting in an eight-fold expansion of
thymocytes (Shortman et al., 1996; Zlotnik et al., 1995; Penit et al., 1995).
During the late pre-T-cell stage, rearrangement and expression of the TCR-p loci
begins (Shortman et al., 1996; Zlotnik et al., 1995). Newly synthesized TCR-a
chains appear to displace pre-Ta chains, and the a(3TCP complex supplants the
pre-TCR complex. After this event, expression of the pre-TCR gene is turned
off, and early, large-sized double positive (DP)(CD4+ CD8+) thymocytes evolve
into small resting DP thymocytes (Saint-Ruf et al., 1994 ).
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b.

Transition to CD4+CD8+

The immature triple-negative thymocytes become CD4+CD8+ after 7 to 9
days in thymus. These cells constitute approximately 80 to 84 percent of the
adult murine thymocytes (Fowlkes et I., 1989). The expression of TCR a and (3
appear to precede the expression of CDS, CD4, and CDS (Petrie et al., 1992).
Weissman (1994) suggests that in humans, the next stage is predominantly
CD4hlCD8', while in most mouse strains, the predominant developmental
intermediate is CD8hlCD4\ These early single positive cells become DP cells
within hours upon culture in vitro or upon intrathymic injection (Kisielow and von
Boehmer, 1995). The independent expression of CD4 and CDS appears to be
attributed to the different signals that are required to up-regulate their
expression. CD4 requires a thymocyte-stromal cell interaction (Brightman et al.
1989; Tatsumi et al., 1990), while the expression of CDS is inducible by thymic
stromal cell derived cytokines such as TGF(3 and TNFa (Suda and Zlotnik, 1992;
Tatsumi et al., 1990). Furthermore, the up-regulation of CD4 and CDS appear to
be signaled through the CDS/TCRp complex that is expressed on DN thymocytes
(Ardouin et al., 1998). This signaling appears to be through the p56lck molecule
since mice deficient for this tyrosine kinase are also blocked at the DN thymocyte
stage (Molina et al., 1992). Humans with a defect in the expression of the CD3e
subunit have a problem in maturing CD8+ T cells (Alarcon et al., 1990), while
humans with a defect in the expression of CD3e subunit have defects in
maturing CD4+ T cells (Thoenes et al., 1992). Finally, IL-1 can induce CD4 and
CDS on thymocytes that have been selected by complement lysis using
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antibodies to CD4, CDS, and CDS (Zimecki and Wieczorek, 1989), but it is not
clear if these cells are CD4 CD8' or CD4l0CD8l0.
c.

Transition to CD4+CD8' and CD4'CD8+

The double-positive thymocytes are subjected to a selection process that
shapes the T cell repertoire (von Boehmer, 1994). These double-positive cells
have a life expectancy of only 3 or 4 days unless they are rescued by
engagement of their T-cell receptor (von Boehmer, 1994). The rescue of
double-positive thymocytes from programmed cell death allows their maturation
into CD4 or CDS single-positive cells, and this rescue process is known as
positive selection (von Boehmer, 1994; Guidos, 1996; Marrack et al., 1997).
Positive selection ensures that mature T cells can recognize foreign or non-self
antigen preferentially in the context of self MHC molecules, and can thus
function in the self MHC restricted responses on which adaptive immunity
depends (Guidos, 1996; Marrack et al., 1997). Double-positive cells also
undergo negative selection: those cells whose receptors recognize self
peptide:self MHC complexes too well are induced to undergo apoptosis, thereby
eliminating potentially self-reactive cells before they mature (Nossal, 1994). In
summary, positive and negative selection ensures that only the rare DP cells
which express a TCP complex being able to recognize self-MHC/peptide
complexes with an appropriate avidity, will develop into mature SP thymocytes.
The result of these selection processes are MHC class l restricted CD4'CD8+T
cells and MHC class II restricted CD4+CD8'T cells (Marrack et al., 1997).
The molecular mechanisms involved in lineage choice during the
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development of DP thymocytes into CD4+CD8' or CD4+CD8' single positive (SP)
cells have been a matter of considerable debate during the last several years
(Chan et al., 1994; Davis et al., 1994; von Boehmer, 1996; von Boehmer et al.
1993). One of the critical questions is how CD4 or CDS expression and MHC
protein specificity are coordinated at the onset of positive selection. Four distinct
CD4/CD8 lineage commitment models have been proposed to explain this
correlation (von Boehmer, 1996).
The instructive model proposes that positive selection occurs at the
double-positive stage of thymocyte development. Co-engagement of the a(3
TCP and the CDS or CD4 co-receptor by either class I or class II MHC molecules
would result in different signals that would direct the differentiation into the CD4'
CD8+ and CD4+CD8' lineages respectively (Kaye et al., 1989; Sha et al., 1988;
Teh et al., 1988).
The stochastic/selective model proposes that thymocytes make a random
choice about which gene to be downregulated, and then co-engagement of
TCRs and co-rceptors by either class I or class II MHC molecules result in
rescue from programmed death of cells with matched receptor molecules only
(Corbella et al., 1994; Crump et al., 1993; Davis et al., 1993). A symmetry for
the generation of CD4, CDS, or both cells is implied by either model. However,
studies by three groups demonstrated that TCR-MHC class I engagement is
required only for the generation of the CDS, but not the CD4 lineage (Lucas et
al., 1996; Lundberg et al., 1995; Suzuki et al., 1995). These results show that
there is an asymmetry in the commitment to the CDS versus the CD4 lineage.
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The default/instructive model proposes that CD4+CD8'commitment occurs
regularly, even in the absence of classical MHC molecules, whereas
commitment to the CD4'CD8+lineage requires an instructive signal delivered
when TCR and CDS coreceptor bind to class I MHC molecules (Suzuki et al.
1995). According to this model, differentiation into CD4+CD8' T cells might be a
default pathway unless a signal from the cytoplasmic tail of an MHC-engaged
CDS is also received by the cells (Punt et al., 1996). To complete the circle of
CD4/CD8 lineage commiment models and experiments that are consistent with
them, Itano et al. report that a CD8a/CD4 chimeric transgene, in which the CD4
cytoplasmic tail has been hooked into the CD8a extracellular and
transmembrane region, engages signifcantly more p56lck than a CD8a transgene
when expressed together with a CD8a transgene (Itano et al., 1996). The same
transgene causes an increase in CD4+CD8' cells that express a class I MHCrestricted TCR.
The instructive/selective model proposes that quantitative differences in
signaling induced by co-engagement of TCR and co-receptors by either class I
or class II MHC molecules produce a bias in lineage commitment such as the
stronger signal favors CD4+CD8' and the weaker signal favors CD4 CD8
commitment. After receptor downregulation, a confirmatory step due to co
engagement of TCRs and co-receptors ensures survival of those cells with
matched TCR and co-receptor expression, while others die (von Boehmer,
1996). Thus, it may be premature to conclude that commitment to the CD4 and
CDS lineages occurs by distinct mechanisms.
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Studies during the last decade indicate that the CD4 and CDS molecules
contribute to the positive selection process by influencing both the avidity of the
TCR-MHC interaction and the signaling function of the ligated TCR complex
(Miceli et al., 1993; Killeen et al., 1996; Zamoyska et al., 1996). The CD4 and
CDS molecules function as co-receptors, interacting with membrane-proximal
domains of the MHC molecules (Garica et al., 1996; Gao et al., 1997), thus
permitting simultaneous interaction of the TCR and either CD4 or CDS with MHC
and also enhancing signaling owing to the increased proximity of the co
receptor-bound cytoplasmic protein tyrosine kinase p56lck (Rudd et al., 1988;
Veillette et al., 1988) to the TCR complex. The bridging of TCR and co-receptor
in their interaction with MHC/self-peptide complexes is generally required for
appropriate development of DP cells into mature SP thymocytes (and
subsequently also in the activation of peripheral T cells upon recognition of
MHC/antigen complexes). Thus, continued expression of a co-receptor is
thought to be essential to maintain a requisite avidity that permits full maturation
of the SP thymocyte, which is accompanied by changes in the expression of
several surface molecules, including the upregulation of TCRa(3 levels, the
transient expression of CD69, and the downmodulation of HSA expression
(Bendelac et al., 1992; Swat et al., 1993). Finally, the selected and mature
thymocytes seed the peripheral immune system, in which expression of either
CD4 or CDS marks the functional phenotype of the mature T cells.
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4.

Post-thymic

a.

T lymphocyte migration into tissue

Once the lymphocytes have completed their development in the thymus,
they enter the bloodstream for re-circulation. During re-circulation, resting naive
lymphocytes reside in secondary lymphoid tissues such as lymph nodes for an
estimated 10-20 hours, assuming that interaction with antigen on appropriate
antigen-presenting cells (APCs) does not occur. The cells then exit through the
efferent lymphatic ducts, ultimately draining into the thoracic duct lymph and
rejoining the blood, and continuing to re-circulate for the duration of their lifespan
(Mackay et al.,1992; Girard et al., 1995). However, when an immune response
is initiated in the CD4 population by presentation of peptide antigen associated
with MHC class II on APCs with the capacity for co-stimulation, a change occurs
in the characteristic pattern of re-circulation (Mackay et al.,1992). Notably,
almost immediately following antigen challenge, lymphocytes are retained within
that site for a day or more, termed the “shut down” phase of the CD4 cell
response (Mackay et al.,1992). During this time, rapid proliferation and
differentiation of T cells within the paracortical regions occurs, and some cells
move to the follicles where the germinal center reaction characterized by
extensive B-cell proliferation takes place, accompanied by somatic mutation and
isotype switching (MackLenna et al., 1994). Subsequently, lymphocyte output
increases above baseline for several days, with the now activated T cells
representing a major population exiting the responding lymphoid tissue (Mackay

et al.,1992).
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b.

T cell activation

Triggering of resting T cells involves interaction with cells bearing the
appropriate antigen in the context of MHC molecules (Altman et al., 1990;
Janeway and Bottomly, 1994). The binding event initiates a cascade of
biochemical changes and generates signals that are transmitted sequentially
from the cell surface to the nucleus, where genes are activated or inhibited
(Lawrence et al., 2000). This gives rise to activated and differentiated T cells
displaying genetically determined effector functions, such as secretion of
immunoregulatory cytokines by T helper cells and specific lysis of target cells by
T cytotoxic cells.
The activation mechanisms of T cells have been extensively analyzed:
upon recognition of the peptide-MHC complex, the initial activation starts with
the phosphorylation of ITAMs (immunoreceptor tyrosine-based activation motifs)
within CD3^ chains by the src tyrosine kinases, p56lck and Fyn; this is followed by
the recruitment of a second family of tyrosine kinases, ZAP-70 or Syk, to the
phosphorylated ITAMs; then phosphorylation and activation of these kinases
occurs to transmit the downstream signal cascades (Weiss et al.,1994; Takashi
et al., 1998). The activation by the TCP: CD4 or CDS co-receptors are known to
associate with non-polymorphic region of MHC class II or I, respectively and are
responsible for efficient recruitment of p56lck to the TCP complex. In addition, on
the cell surface, considerable numbers of other molecules are involved in initial
recognition: CD28 provides co-stimulation signals by interacting with the ligands
CD80 and CD86 on antigen-presenting cells or target cells (Reinhold et al.,

34

1997); lymphocyte function-associated antigen (LFA)-1 and very late antigens
(VLAs) play important roles in T cell activation through general cell-cell adhesion
between T cells and APCs (Tanina et al., 1999); and adhesion molecules such
as 4-1BB ligand (DeBenedette et al.,1997), CD47 (Reinhold et al., 1997) and
CD9 (Tai et al., 1996) also have a co-stimulatory function to augment T cell
activation.
By activation, the naive CD4+ T cells can further develop into two
subsets: Th1 cells and Th2 cells. Th1 cells and Th2 cells have very different
functions: the Th 2 cells secrete IL-4, IL-5, IL-6 and IL-10 and are effective in
infections involving extracellular pathogens (Xu-Amano et al., 1993). The Th1
cells are crucial for activating macrophages provide defense against intracellular
pathogens, secreting both TNF-a and IFN-y in addition to IL-2 and TNF-P
(O'Garra et al., 1994). In gut mucosal tissues, the predominant responses
involve Th2 cells, which secrete IL-4, IL-5, IL-6 and IL-10 and are effective in
infections involving extracellular pathogens (Xu-Amano et al., 1993).
Analyzed recently using knockout mice, T cells activated in the presence
of IL-4 or IL-12 acquire highly polarized phenotypes, revealing the importance of
specific signaling pathways for Th1/Th2 development (Kenneth et al.,1998). For
IL-12 induced Th1 development, activation of a specific signaling molecule
Stat4, appears essential for inducing Th1 development (Kaplan et al., 1996a)
and State activation by IL-4 was essential for Th2 development (Shimoda et al.
1996; Kaplan et al., 1996b; Takeda et al., 1996). Thus, early IL-12 or IL-4
production becomes a critical point of control. The importance of early cytokines
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effects were also emphasized by the observation that 48 h after primary
activation, Th1 or Th2 cells are polarized towards their pathway, and rapidly
extinguish the expression of cytokines produced by the opposite lineage
(Nakamura et al., 1997). IFN-y not sufficient for Th1 development may help
regulate the ability of T cells to respond to IL-12 (Wenner et al., 1996); moreover,
Th2-inducing conditions cause a rapid decrease in IL-12 signaling (Szabo et al.,
1995), allowing early Th2 stability. Furthermore, Fowell and co-workers (Fowell
et al.,1997) have recently suggested that CD4 may contribute to Th2
development. Th2 development in CD4-deficient mice was significantly impaired
in several paradigms suggesting that CD4 signaling in the periphery contributes
to the pathways required for IL-4 induced Th2 development.
Recently, a cell surface protein, CTLA-4, has been identified having a
function to inhibit the T cell activation (Waterhous et al.,1997; Tivol et al., 1995;
Van der Merwe et al., 1997). Strong evidence to support the inhibitory role of
CTLA-4 was provided by analysis of mice deficient in CTLA-4 (CTLA-4^)
(Waterhous et al.,1997; Tivol et al., 1995). Null mutant mice of CTLA-4 exhibited
a massive lymphoproliferative disorder that resulted in splenomegaly and
lymphadenopathy and the mice died between three and four weeks of age
(Waterhous et al.,1995; Tivol et al., 1995). The majority of peripheral T cells in
these mice was in an activated state and exhibited spontaneous production of
cytokines. CTLA-4 is a transmembrane glycoprotein belonging to the
immunoglobulin superfamily and is homologous to CD28 which mediates positive
co-stimulation for T cell activation (Chambers et al., 1997). Both CD28 and
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CTLA-4 bind to the same ligands, CD80/CD86, through the motif
Met-Tyr-Pro-Pro-Tyr in the variable domains of the extracellular regions of
CTLA-4/CD28 (Peach et al., 1994). The important difference between CTLA-4
and CD28 lies in their affinity for their ligands — CTLA-4 has an affinity 10-fold
higher than CD28 (Van der Merwe et ai., 1997). This implies that a low level of
CTLA-4 expression may diminish activation through CD28 by competitive binding
to ligands; furthermore, CTLA-4 shows much higher ligand avidity than CD28
when the ligands form disulfide-linked homodimers (Greene et al., 1996).
The regulation of the cell surface expression of CTLA-4 is crucial for its
suppressive effects. Whereas resting T cells do not express the surface CTLA4, activated T cells do express CTLA-4 on the cell surface, but the number of
molecules expressed is still only a small percentage of the number of CD28
molecules expressed (Linsley et al., 1992). This difference in cell surface
expression between CD28 and CTLA-4 supports the concept that CTLA-4
delivers inhibitory signals into cells rather than competing for ligand binding with
CD28 on the cell surface.
c.

CD4 Modulation

Although the normal functions of CD4 require its expression at the plasma
membrane, CD4 can be rapidly down-regulated from the surfaces of T cells by a
variety of stimuli such as exposure to an appropriate antigen (Rivas et al., 1988;
Weyand et al., 1987) or treatment with cross-linking antibodies against CD4
(Cole et al., 1989), the CD3/TCR complex (Rivas et al., 1988) or CD2 (Blue et
al., 1989). Most of these stimuli operate through the activation of protein kinase
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C (PKC) (Pelchen et al., 1993). The most effective triggers for CD4 downregulation are PKC-activating phorbol esters such as phorbol myristate acetate
(PMA) or phobol dibutyrate (PDB) (Pelchen et al., 1993). In addition to the
down-regulation induced by T cell activation and phorbol esters, cell surface
expression of CD4 could be modulated via receptor-mediated endocytosis
(Wang et al., 1992). Endocytotic vesicles and vacuoles of different sizes and
shapes contain CD4 after the T cell is activated by IL-2. These vesicles are
located near the cell membrane and deep in the cell center. The internalized
CD4 molecule can be targeted to be degraded or the CD4 molecule can recycle
to the cell surface (Pelchen-Matthews et al., 1993).
1)-

Alterations in Response to Chemical Agents

There are a number of chemical agents which mimic T cell activation and
can down-modulate the cell surface expression of CD4. Phorbol esters, such as
phorbol 12-myristate 13-acetate (PMA) (Shin et al., 1990; Solback, 1982), induce
the internalization of CD4. Activation of protein kinase C (PKC) (Hamamoto et
al., 1989) and phosphorylation of CD4 (Blue et al., 1987) are central to phorbol
ester induced CD4 endocytosis. Activation of PKC induces CD4 to dissociate
from p56lck (Hurley et al., 1989) possibly through phosphorylation of three serine
residues in the CD4 cytoplasmic tail (Shin et al., 1990). Disruption of the
CD4/p56lck complex is necessary for rapid internalization of CD4 (Sleckman et
al., 1992). To initiate disruption of the CD4/p56lck complex, which precedes
PMA-induced CD4 internalization, phosphorylation on serine 408 may be
necessary (Sleckman et al., 1992; Hurley et al., 1989). In fact, p56lck may delay
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or inhibit CD4 endocytosis by preventing entry of CD4 into coated pits (Yoshida
et al., 1992; Pelchen-Matthews et al., 1992). Interestingly, PMA down-modulates
CD4 on mature human T cells but not mature mouse T cells (Sleckman et al.
1989). PMA does down-modulate CD4 on murine CD4+CD8+ thymocytes (Wang
et al., 1987).
Bryostatins, macrocyclic lactones isolated from Bugula neritina (Pettit et
al., 1982), can down-modulate cell surface expression of CD4 (Esa et al., 1990;
Boto et al., 1991). Bryostatins are structurally distinct from phorbol esters, but
can bind and activate protein kinase C (PKC), the cellular receptor for phorbol
esters, and elicit PKC-dependent cellular functions (Berkow and Kraft, 1985;
Hess et al., 1988). A commonly used bryostatin, bryo-1, inhibits the
glycosylation and expression of CD4 in a manner similar to that of tunicamycin
an N-linked glycosylation inhibitor (Boto et al., 1991).
Gangliosides, sialic acid containing glycosphinglipids, are ubiquitous
constituents of cell membranes (Hakomori, 1990). In T lymphocytes they seem
to play a role in cell-cell interactions, antigen recognition, activation, and signal
transduction (Whisler and Yates, 1980). Some gangliosides, such as GM1, are
virtually undetectable in the lymphocyte plasma membrane, while others, like
GM3, represent approximately 70 percent of the ganglioside content in these
cells (Kiguchi et al., 1990). Treatment of CD4+ T lymphocytes with GM1, or
ganglioside derivatives, reduces CD4 surface expression (Offner et al., 1987;
Kawaguchi et al., 1989; Grass! et al., 1990; Repke et al., 1992; Saggioro et al.,
1993). This effect on CD4 may be due to masking of CD4 epitopes (Offner et
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al., 1987; Grassi et al., 1990; Chieco-Bianchi et al., 1989), shedding of CD4
(Morrison et al., 1991), or endocytosis (Offner et al., 1987; Kawaguchi et al.
1989; Repke et al., 1992; Saggioro et al., 1993). GM3 also induces
down-modulation of cell surface CD4 by endocytosis (Sorice et al., 1995). The
actual mechanism of ganglioside induced CD4 endocytosis is unclear since both
a serine phosphorylation independent pathway involving dissociation of p56 Ick
(Repke et al., 1992; Saggioro et al., 1993; Sorice et al., 1995) and a pathway
independent of p56lck (Soho et al., 1993) have been implicated.
2).

CD4 Down-Modulation During HIV Infection

Infection of CD4 positive cells by the human immunodeficiency virus
(HIV) leads to the loss of cell surface CD4 on the infected cells (Hoxie et al.
1986; Stevenson et al., 1987; Salmon et al., 1988; Geleziunas et al., 1991). Cell
surface alteration of CD4 occurs early in infection, during HIV-1 structural protein
expression, and during the expression of auxiliary proteins (Bour et al., 1994).
Mechanisms that may cause HIV-1 associated cell surface CD4 depletion
include endocytosis (Amadori et al., 1992; Cefai et al., 1992; Garcia et al., 1993)
reductions in transcript levels of CD4 (Hoxie et al., 1986a; Salmon et al., 1988)
impaired translation of CD4 mRNA (Geleziunas et al., 1991; Yuille et al., 1988)
intracellular retention of CD4 (Bour et al., 1991; Crise and Rose, 1992; Jabbar
and Nayak, 1990), and CD4 degradation (Willey et al., 1992; Chen et al., 1993).
Early in infection, CD4 is down-modulated after cell-surface binding of
virions. Soluble gp120, or antigen-antibody complexes that involve gp120, mask
cell surface CD4 (Amadori et al., 1992). Furthermore, after binding of gp120

40

antigen-antibody complexes or gp120 alone, CD4 is internalized by a serine
phosphorylation independent pathway (Amadori et al., 1992; Cefai et al., 1992).
In addition, Chronic exposure of CD4 T cell lines to recombinant gp120 can lead
to dissociation of p56lck and, as a consequence, to limited downregulation of
CD4 (Juszcznk et al. 1991; Cefai et al. 1992). CD4 is gradually up-modulated
when soluble gp120 is removed (Cefai et al., 1992).
CD4 is associated intracellularly with gp160 in productively infected cells
(Bour et al., 1991; Salmon et al., 1988; Shahabuddin et al., 1992). Cell lines
which express gp160 not only have internal CD4/gp160 complexes, but also
have a reduced level of cell surface CD4 (Stevenson et al., 1988; Crise et al.
1992; Jabbar et al., 1990). Furthermore, intracellular levels of gp160 are
inversely correlated with cell surface CD4 levels (Stevenson et al., 1988; Koga et
al., 1990). Retention in the endoplasmic reticulum seems to depend on
membrane anchorage, since CD4/gp160 complexes can anchor via the
COOH-terminal transmembrane segment of gp41, while CD4/gp120 complexes
cannot anchor and are transported from the endoplasmic reticulum (Crise and
Rose, 1992).
CD4 down-regulation is also related to the expression of two HIV-1
proteins, Nef and Vpu. Nef is expressed during the early regulatory phase of
HIV-1 gene expression in a Rev-independent fashion, whereas Vpu is expressed
during the structural phase of HIV-1 gene expression in a Rev-dependent
manner (Cullen, 1991). Nef expression in thymocytes of transgenic mice or in
CD4+ cell lines led to the down-regulation of CD4 surface expression (Garcia et
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al., 1993; Skowronski et al., 1993), but did not affect levels of CD4 mRNA or
protein. Furthermore, the effect of Nef does not appear species-specific, as it
occurs with human and murine CD4 (Garcia et al., 1993; Skowronski et al.
1993). The down-regulation of CD4 by Nef requires the cytoplasmic tail of CD4,
but does not involve the cytoplasmic tail serine residues (Garcia et al., 1993)
suggesting that the mechanism may be serine-phosphorylation independent
endocytosis. Vpu can induce degradation of CD4 in the presence (Willey et al.
1992; Chen et al., 1993) or absence (Willey et al., 1992) of gp160. The target
for Vpu-associated degradation of CD4 appears to be the cytoplasmic domain of
CD4, and involves the hydrophilic COOH terminus of Vpu (Chen et al., 1993).
So by degrading CD4, Vpu reduces the quantity of CD4/gp160 complexes and
enhances gp160 processing.
3).

Summary of CD4 Down-Modulation

In summary, CD4 expression is modulated during T cell activation and
also by a number of chemical and infective agents. Cell surface expression of
CD4 is reduced during T cell activation by antigen, anti-CD3 alone, anti-CD4
alone, PMA alone, bryostatins, gangliosides, HIV infection, gp120, gp160, Nef
and Vpu.

C.

TRANSCRIPTIONAL CONTROL OF THE CD4 GENE
1.

CD4 Promoter

a.

C/s-acting elements

The murine CD4 promoter has been characterized by in v/Yro transfection
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studies (Siu et al., 1992; Duncan et al., 1995). The 101 bp 5' of the
transcripitional start site is the minimal sequence required for full function of the
CD4 promoter. An analysis of the sequence immediately upstream of the
transcriptional start site does not reveal a consensus TATA sequence, CCAAT
box or GC-rich region, although a pyrimidine rich region exists around the start
site that is characteristic of initiator (Inr) sequences (Siu et al., 1992; Nakayama
et al., 1993). Within the CD4 promoter there are four functional regions which
bind T cell nuclear factors (Duncan et al., 1995): 1) A Myb family member binds
to site 1 (Siu et al., 1992); 2) sequence analysis shows homology of site 2 to the
ME1a1 site of the Myc promoter (Asselin,1989); 3) site 3 is similar in sequence
to the NF1/CTF recognition site (Ghosh,1992); 4) and there is an Ets family
consensus sequence within site 4 (Duncan et al.,1995). Mutations in any of
these four sites reduce promoter activity by more than 60% (Duncan et al.,1995).
The human CD4 promoter is similar to the murine CD4 promoter (Salmon
et al., 1993). The human CD4 core promoter has been identified as a 56 bp
fragment (-40 to +16) which functions in a tissue-specific fashion. Sequence
analysis indicates no consensus promoter sequences, such as a TATA box,
CCAAT box or initiator, in the vicinity of the transcription start site. But the
human CD4 core promoter does contains three regions which are identical to
regions in the murine CD4 promoter. The location of these three regions of
homology suggests that they could be involved in RNA polymerase complex
assembly (Salmon et al., 1993). The human CD4 promoter is activated by Ets
proteins (Salmon et al., 1993).
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b.

Trans-acting factors

At least four distinct transcription factors are required for the activity of the
murine CD4 minimal promoter (Duncan et al.,1995). Myb recognition sequences
at site 1 are essential for the activity of the CD4 promoter. c-Myb can bind to this
site. The Myc-associated zinc finger protein (MAZ) transcription factor binds to
site 2. An Ets-related transcription factor binds to site 4 and is important for full
promoter function. Recently studies have shown that Elf-1 and not Ets-1 or Ets-2
binds to the site 4 and mediates CD4 promoter function (Sarafova et al., 1999).
c.

Intronic promoter

An intronic promoter has been identified within the first intron of the
human CD4 gene (Rushton et al., 1997). The basal promoter has been localized
to a 32 bp fragment at the 3' end of first intron of human CD4 gene. This basal
promoter lacks potential binding domains for Myb and Ets, both of which have
been shown to be involved in the function of the murine and human CD4
promoter. Sequence analysis of the intronic promoter indicates the potential
transcription factor-binding sites for AP2, LBP1, c-/r?os-DS1 and CK-8-mer
(Rushton et al., 1997).
d.

The role of the promoter in tissue-specificity and stagespecificity

The murine CD4 promoter functions in a stage- and tissue-specific
manner (Siu et al., 1992), whereas the human CD4 promoter functions in a
tissue-specific manner (Salmon et al., 1993). The CD4 promoter is relatively T
cell subclass-specific, as it has preferential activity in CD4+ T cell lines compared
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with CD4'CD8+ cell lines (Salmon et al., 1993; Siu et al., 1992). However, the
findings of subclass-specificity in these studies are hard to reconcile with the
observation that a combiniation of CD4 enhancer and promoter directs reporter
gene expression in both CD4 SP and CDS SP cell lines (Sawada and Littman,
1991). Furthermore, recent studies in transgenic mice indicate that, in the
presence of the CD4 enhancer, the CD4 promoter is not sufficient for subclassspecific expression (Sawada et al., 1994; Siu et al., 1994). One possible
explaination for this discrepancy is that the CD4 promoter is preferentially active
in the CD4 subset, but its specificity is overridden by the presence of the CD4
enhancer (Killeen and Littman, 1996). Alternatively, it is possible that the
discrepancy is caused by performing in w'fro transactivation assays in cell lines
that might not properly reflect the transcriptional regulation and specificity
observed in T cells in vivo. Furthermore, the promoter activity is possibly
regulated by the concentration of the somewhat ubiquitous T cell trans-acWng
factors that exist in higher concentration in CD4+T cells than in CD4 T cells. The
concentration of such factors might cause the subclass-specific expression of
CD4 promoter. Indeed, the Ets protein is 10-20 times higher in concentration in
CD4+ T cells than in CD4 T cells (Salmon et al., 1993) and Ets factors have been
shown to be able to interact cooperatively with a variety of other transcription
factors which include Myb, core-binding factor, AP-1 and Sp1 (Dudek et al.
1992; Gegonne et al., 1993; Wang et al., 1994). In addition, Myb is expressed at
high levels in immature CD4 CD8' and CD4+CD8+ thymocytes but at low levels in
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the more mature CD4+CD8' and CD4'CD8+ thymocytes (Sheiness and Gardinier,
1984; Thompson et al., 1986).
The intronic promoter functions in T cell lines and is preferentially active in
immature DP T cells (Rushton et al., 1997). Transcriptional regulation by
multiple promoters has been reported for other genes (Campos et al., 1992;
Courchesne-Smith et al., 1992; Hu et al., 1997; Yamasaki et al., 1991). Mostly,
the involvement of multiple promoters is associated with developmental and
tissue-specific expression patterns. The exact function of this internal promoter
in the developmental regulation of CD4 expression needs to be further
determined.
2.

CD4 Enhancer

a.

C/s-acting elements

Two enhancers in the 5' region of the murine CD4 gene have been
identified (Sawada and Littman, 1991; Wurster et al., 1994). The distal murine
enhancer is 25 kb 5' of the CD4 gene (Wurster et al., 1994). The activity of the
distal enhancer is restricted to mature T cells, especially CD4+ helper T cells.
The LAG-3 gene, a gene up-regulated in activated T cells (Trieble et al., 1990),
is positioned between the distal and proximal enhancers. The distal enhancer is
probably the enhancer for the LAG-3 gene while the proximal enhancer is
probably the enhancer for the CD4 gene.
The proximal enhancer, present within a 800 bp Nde\-Hinf\ restriction
fragment, is located approximately 13 kb 5' of the murine CD4 promoter and is T
cell-specific (Sawada and Littman, 1991). A 339 bp BstX\-Ava\\ restriction
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fragment within this proximal enhancer is as effective in stimulating the CD4
promoter as the larger 800 bp restriction fragment, indicating that this 339 bp
fragment contains the minimal enhancer (Sawada and Littman, 1991). This
minimal enhancer is referred to as the enhancer of the CD4 gene in this
dissertation. The enhancer is active in CD4' as well as in CD4+ T cell subsets
indicating that the minimal enhancer is T cell-specific but not subclass-specific
(Sawada and Littman, 1991).
DNase I footprint analysis and electrophoretic mobility shift assays
(EMSA) identified three nuclear protein binding sites, CD4-1, CD4-2 and CD4-3
within the murine CD4 minimal enhancer (Sawada and Littman, 1991). The
CD4-1 and CD4-3 sites both contain the E-box motif, CANNTG. The CD4-3 site
contains two E-boxes separated by a single base pair. The CD4-2 site contains
a consensus binding sequence for the HMG (high mobility group) family
members TCF1a/LEF1 (Clevers and van de Wetering, 1997). However, binding
of TCF1a/LEF1 was largely dispensible for activity in transient transfection
assays (Sawada and Littman, 1993). Mutational analysis of the CD4-1 and CD42 binding sites indicate that CD4-1 and CD4-2 are not essential for
transcriptional activity in T cells. In contrast, mutation of both E-boxes within the
CD4-3 sequence abolishes enhancer activity. This result suggests that the
binding of one or more E-box-binding proteins, which are members of the basic
helix-loop-helix (bHLH) family of transcription factors, to one or both motifs in
CD4-3 is essential for the T cell-specific activity of this enhancer (Sawada and
Littman, 1991).
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The human CD4 enhancer has been identified as a 1.3 kb fragment
located 6.5 kb 51 of the human CD4 gene (Blum et al., 1993). This CD4
enhancer functions in a T cell-specific manner in vivo (Blum et al., 1993).
Sequence comparison between the human and murine enhancers reveals that
the CD4-3 site is the only conserved element of the three murine protein/DNA
binding sites. The CD4-2 is not conserved in the human enhancer even though
the function of CD4-2 which interacts with TCF-1a/LEF-1, was stressed by
Sawada and Littman (1991) when they analyzed the murine enhancer. In
addition, DNA sequences surrounding, and within, the human CD4 enhancer are
homologous to regions surrounding and within the murine minimal enhancer
(Blum et al., 1993) suggesting that the DNA surrounding the murine minimal
enhancer may also be important to enhancer function.
b.

Trans-acting factors

A number of nuclear proteins crucial for enhancer activity have been
identified which bind to elements in the minimal CD4 enhancer. The T cell and
pre-B cell-specific nuclear factor, LEF, binds to the CD4-2 site through its binding
motif, CANAG. The E-box-binding proteins of the bHLH family, which bind to
CD4-1 and CD4-3, are involved in regulating tissue-specific transcription of
numerous genes. Some of these factors are thought to function as central
regulators of cell type determination. Three nuclear protein complexes have
been identified within the CD4-3 site, CD4-3A, CD4-3B and CD4-3C (Sawada
and Littman, 1993). The CD4-3A site contains the 5' E-box and binds HEB and
an E12-related protein.
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c.

The role of the CD4 enhancer in tissue- and stage-specificity

It has been shown that the murine CD4 enhancer is T cell-specific but not
subclass-specific (Sawada and Littman, 1991) and the human CD4 enhancer
functions in a T cell-specific manner in vivo (Blum et al., 1993). Transgenes in
which either human or murine proximal enhancer was linked to a hCD4 minigene
directed expression of hCD4 on both peripheral T lymphocytes and thymocytes
in mice (Blum et al., 1993; Gillespie et al., 1993; Hanna et al., 1994; Killeen et
al., 1993). However, in the absence of the enhancer, low level subclass-specific
expression of hCD4 could be detected in mature CD4 SR T cells, but not in DP
thymocytes. The inclusion of the murine enhancer increased CD4 levels on
mature T cells and resulted in expression in DP thymocytes (Hanna et al., 1994).
The function of the enhancer was also confirmed using a murine transgene that
contained a human CD2 cDNA as a reporter gene driven by the murine CD4
promoter (Sawada and Littman, 1991). Taken together, these results suggest
that the CD4 enhancer is required for high level expression and for tissuespecificity of the transgenes in vivo.
One group was unable to confirm enhancer activity for the proximal
murine enhancer (Siu et al., 1992). However, studies in transgenic mice
confirmed the presence of a T cell-specific enhancer in this region which is
capable of stimulating an increased level of T cell-specific transcription (Blum et
al., 1993; Killeen et al., 1993; Hanna et al., 1994). Salmon et al. (1996) found
that the CD4 promoter alone, without the CD4 enhancer or the first intron, does
not function in transgenic mice. This is in contrast with reports showing that the
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CD4 promoter alone can function in mature CD4+ helper T cells (Siu et al.
1992), indicating that although the CD4 promoter displays a strong and tissuespecific activity in transfected cells, the presence of an enhancer is essential for
appropriate expression of the CD4 gene in a developmental setting.
3.

CD4 silencers

a.

C/s-acting element

Wilkinson et al., (1991) illustrated the dominant aspects of negative
control of the murine CD4 gene. Sands and Nikolic-Zugic (1992) identified the
presence of two T cell-specific DNase I hypersensitive (DH) sites in the first
intron. DH site 9 (DH9) correlates with the absence of expression of CD4 in
thymocytes and mature T cells, while DH site 10 (DH10) does not vary once the
pro-T cell enters the thymus. Their work was the first to suggest that DH9 may
be an important silencer in down-regulating CD4 expression. In addition, early
studies in transgenic mice have also implicated the importance of the first intron
in controlling subclass-specific CD4 expression (Blum et al., 1993; Gillespie et
al., 1993; Hanna et al., 1994; Killeen et al., 1993).
Subsequently, a transcriptional silencer was identified within the first intron
(Sawada et al., 1994; Siu et al., 1994). The murine CD4 intronic silencer has
been narrowed down to a 428 bp fragment located approximately 2.5 kb 3' of the
transcription start site (Sawada et al., 1994). This murine silencer corresponds
to DH9 (Sands and Nikolic-Zugic, 1992). By using DNase I footprinting, three
factor-binding sites have been identified within this 428 bp murine silencer
(Duncan et al., 1996). Deletion of any one of the three sites does not affect
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silencer specificity or function, but double deletions of either site I/site II or site
ll/site III abrogate silencer function, suggesting that there is an asymmetric
redundancy in the mechanism of CD4 silencer function (Duncan et al., 1996).
This murine CD4 intronic silencer functions in a position- and orientationindependent way (Sawada et al., 1994; Siu et al., 1994), and it is active in
combination with a heterologous enhancer and promoter from the CD3d gene
(Sawada et al., 1994). Transcriptional silencing by the CD4 intronic enhancer
has been reproduced in a transient transfection assay, but only when multiple
copies of the element were included (Sawada et al., 1994).
In addition, a subclass-specific silencer was also identified within a 484 bp
Rsa\ fragment in the first intron of the human CD4 gene (Donda et al., 1996). Its
sequence is 77% identical to that of the murine silencer. Further experiments
have shown that the 5' 190 bp of this fragment, which overlaps the 5' sequence
1-173 of the murine silencer, is sufficient to direct silencing in transgenic mice
(Donda et al., 1996). In the human intronic silencer, two protein-binding sites
were detected in the 190 bp fragment (Donda et al., 1996). Tested in transient
transfection assays, these two sites showed significant silencing activity
restricted to the CDS SR T cells. One of these corresponded precisely to site I in
the murine silencer, whereas the other did not correspond to any footprints in the
murine silencer (Duncan et al., 1996). Comparison of the results of these
studies suggests that there are different requirements for human versus murine
silencer function in transgenic mice (Donda et al., 1996; Duncan et al., 1996).
Thus, the murine silencer is inactive if sequences corresponding to footprints II
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and III are both deleted, even though sequence 1-173 is fully intact (Duncan et
al., 1996). In contrast, the human sequence corresponding to murine silencer
sequence 1-173 is sufficient for in vivo function (Donda et al., 1996).
b.

Trans-acting factors

Duncan et al., (1996) found that the factor binding to site II of the murine
CD4 intronic silencer has the same sequence specificity as a factor binding to
the E-box site of the proximal CD4 enhancer. Since the factor binding to the
CD4 enhancer belongs to the bHLH factor family, the factor binding to site II
also appears to be a member of the bHLH factor family. The identity of the
factors binding site I and site III are unknown. Siu and colleagues demonstrated
that HES-I binds to the CD4 silencer region (Ellmeier et al., 1999). HES-I is the
mammalian homologue of the Drosophila Notch signaling pathway mediators
Enhancer of split. Transient overexpression of HES-1 in D10 CD4 SR Th cells
resulted in an approximately 60% repression of CD4 promoter and enhancer
activity that was dependent on the presence of a functional HES-I binding site
within the silencer region.
c.

The role of the silencer in stage- and tissue-specificity

The 428 bp intronic region down-regulates CD4 expression in CD4 CD8'
and CD4'CD8+ T cells, but does not appear to regulate CD4 expression in non-T
cells. Sui et al (1994) demonstrated that the CD4 silencer functions at three
stages of development: 1) it functions to inhibit CD4 gene expression in non-T
hematopoietic cells; 2) the silencer inhibits expression of CD4 in the CD4 CD8'
population, an early precursor stage in the thymus. As the thymocyte matures
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into a CD4+CD8+ T cell, the silencer ceases to down-regulate the CD4 promoter,
permitting the expression of CD4; 3) either during or after the T cell repertoire
selection processes, the CD4 silencer may either remain non-functional
resulting in a CD4+CD8' T helper cell, or resume function, thus silencing the CD4
gene and leading to the development of a CD4"CD8+ cytotoxic T cell. This model
suggests that the CD4 silencer functions to inhibit marker gene expression at two
different stages of T-cell development, as well as in non-T hematopoietic cells,
and thus is the critical controlling element responsible for T cell-specific, as well
as developmental- and subclass-specific expression.
d.

The role of silencers in transcriptional regulation in
eukaryotes

Transcriptional repression in eukaryotes is achieved through “silencers”
of which there are two types, namely “silencer elements” and “negative
regulatory elements” (NREs) (Ogbourne and Antalis, 1998). Silencer elements
are classical, position-independent elements that direct an active repression
mechanism, and NREs are position-dependent elements that direct a passive
repression mechanism (Ogbourne and Antalis, 1998). In addition, “repressors”
are DNA-binding trasncription factors that interact directly with silencers.
Silencers were initially defined as sequence elements which are capable of
repressing promoter activity in an orientation- and position-independent fashion,
in the context of a native or a heterologous promoter (Brand et al., 1985).
However, in practice, a silencer is now generally considered to be a specific
sequence of nucleotides which are located in the 5' upstream promoter region of
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a given gene. There are three characteristics of the silencers (Siu et al. 1994):
1) the negative regulatory element functions as a transcription inhibitor; 2) the
silencer element can be separated from the enhancer element, whereas most
repressor sequences are directly adjacent to other transcriptional control regions;
3) when the negative regulatory element is located at a different position and
distance from the promoter in transgene constructs than it is in the genomic
gene, it functions in a position- and distance-independent fashion. The CD4
intronic silencer has these three characteristics.
The mechanism through which silencing is achieved is not yet fully
understood. It may involve locus inactivation through changes in the structure of
adjacent chromatin, possibly by influencing DNA methylation or the activity of
histone deacetylases; or it may be due to direct interaction of a silencing factor
with the components involved in initiating transcrption of the CD4 gene (Killeen
and Littman, 1996).
Recently, a transcription factor in the lin 12/Notch signaling pathway, the
Hairy/Enhancer of Split homologue HES-1, has been reported to bind to an
important functional site in the CD4 silencer (Kim and Siu, 1998).
Overexpression of HES-1 leads to the silencer site-dependent repression of CD4
promoter and enhancer function as well as the down-regulation of endogenous
CD4 expression in CD4+CD8' T cells. These data are consistent with the
hypothesis that the Iin12/Notch signaling pathway is important in thymic
development and may indicate that Notch signaling induces transcriptional downregulation of CD4 in the CDS lineage via the HES-1 protein (Robey et al., 1996).

54

D.

PREVIOUS WORK DONE IN DR. SANDS’ LABORATORY
The c/s-acting transcriptional control elements of the murine CD4 gene

were investigated by Sands and Nikolic-Zugic (1992). They extensively analyzed
75 kb of chromatin associated with the murine CD4 locus in four T cell lines, a B
cell line, a macrophage cell line, a fibroblast cell line, and a teratocarcinoma cell
line using DH site analysis. Twenty-two DH sites were found in 75 kb of
chromatin (Fig.1.5). Seven of these DH sites are T cell-specific and five
additional DH sites are lymphocyte-specific. The T cell-specific sites are located
in four regions: 1) approximately 3 kb 5' of the first exon; 2) within the first
intron; 3) near the second and third exons; and 4) 3' of the gene. Two cell
type-specific nuclear matrix attachment regions are located 2-5 kb and 10-12 kb
5' of the CD4 gene. One repetitive element is located about 6-9 kb 5' of the first
exon and another is located in the third intron of the CD4 gene. Most of the T
cell-specific sites have been subcloned and each has a T cell-specific
protein/DNA interactions associated with it. The DH site analysis of the CD4
locus suggests that the transcriptional regulation of CD4 is complex and involves
numerous protein/DNA interactions occurring 51 of the gene, within the first and
third intron, and perhaps even 3' of the gene. DH5 corresponds to the CD4
enhancer (Sawada and Littman,1991); DH8 is located at the 5' end of the first
exon, near or at the promoter; DH9 corresponds to the silencer located 2.5 kb 3'
of the promoter (Sui et al.,1994; Sawada et al., 1994); and DH10 is 4 kb 3' of
DH8.
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DH10 has been characterized as a second intronic negative control element of
the CD4 gene (Hansen,1995). The DNA/protein interaction of this element is T
cell-specific, and involves a TATC (or GATA) repeated sequence (Hansen
1995). In addition to the silencers found within the first intron, three other
regions of DMA 5' of the CD4 gene, corresponding to DH6 and DH7, repress
transcription from the CD4 promoter.
The first intron also contains one or more positive control elements.
Transfected reporter constructs that include the 5' enhancer, the CD4 promoter
and these two intronic fragments express the reporter 16-fold higher than do
transfected constructs that do not contain these two intronic fragments indicating
that a DMA region within the first intron is essential for the 5' enhancer to fully
stimulate the CD4 promoter.

E.

Specific Aims
The murine CD4 enhancer has been identified as a 339 bp region

approximately 13 kb upstream of the CD4 gene (Sawada and Littman, 1991).
The human CD4 enhancer has been identified as a 1.3 kb region located 6.5 kb
upstream the human CD4 gene (Blum et al., 1993). Sequence analysis shows
that there are 8 regions of homology within the murine CD4 enhancer and the
region outside the minimal enhancer (Blum et al., 1993;). Hansen (1995), by
sequence analysis, found three regions of homology between the murine and the
human enhancer upstream of the murine minimal CD4 enhancer.
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Her work suggests that the CD4 enhancer may be part of a larger regulatory unit
that regulates the CD4 promoter.
Therefore, the specific aims of this dissertation were to:
1.

Characterize the function of the DNA regions 3’ of the murine CD4
enhancer.

2.

Localize the CD4 enhancer elements to a smaller region.

3.

Determine the function of the human homology regions located 5' of the
CD4 enhancer.

4.

Further characterize the functional fragments.
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CHAPTER TWO
II. MATERIALS AND METHODS
A.

MATERIALS
1.

Reagents

QIAGEN Plasmid Maxi kit, and QIAEX II Gel Extraction kit were obtained
from QIAGEN Inc. (Chatsworth, CA). Restriction enzymes, buffers, and
modification enzymes were from Promega Corp. (Madison, Wl) with the
exception of A/ofl, Bcl\, Bal 31 nuclease enzymes, and Not\ linkers which were
obtained from New England Biolabs (Beverly, MA). Bluescript II pKS+ was from
Stratagene (La Jolla, CA). Molecular biology grade agarose was obtained from
Promega Corp. Electrophoresis grade ethidium bromide for staining gels was
from Fisher Scientific (Fair Lawn, NJ). Geneclean II kits were purchased from
Bio 101 (La Jolla, CA). Rapid DNA Ligation kit was obtained from Boehinger
Mannheim (Indianapolis, IN). Bactotryptone, agar, and bacto yeast extract were
from Difco (Detroit, Ml). Ampicillin was from Boeringher Mannheim (Indianapolis
IN). Petri dishes and pasteur pipettes were purchased from Fisher Scientific Co.
(Irvine, CA). Culture flasks, polypropylene tubes, polystyrene pipettes, nylon
disposable filter systems, and cryogenic vials were obtained from Corning Glass
Works (Corning, NY). Dulbecco’s RPMI-1640, L-glutamine, PBS,
Penicillin-streptomycin solution (100X containing 10,000 units of penicillin and
10 mg of streptomycin per ml of 0.9 % NaCI solution), and newborn bovine
serum (NBS) were purchased from Gibco-BRL (Grand Island, NY) and
Mediatech, Inc. (Washington, DC). Newborn calf serum was purchased from

60

Gemini (Calabasas, CA). Monoclonal anti-mouse CD4, CD2a FITC conjugate
and anti-mouse CD8a, CD2a R-phycoerythrin conjugate were purchased from
Sigma Chemical Company (St. Louis, MO). Acrylamide, bis-acrylamide
ammonium persulfate, TEMED, Coomassie Brilliant Blue and Bradford Protein
Determination Reagent were purchased from Bio-Rad Laboratories (Richmond
CA). Vector pGEM-11Zf(+), pCAT basic, pCAT promoter, and pCAT control
were from Promega Corp. Reporter Lysis 5x buffer for CAT assays, N-butyryl
coenzyme A, and the Core Footprinting system were obtained from Promega
Corp. 14C-chloramphenicol was purchased from ANDOTEK Life Sciences
Company (Tustin,CA). Cytoscint scintillation fluid, and y[32P]-ATP
(7000 Ci/mmol) were from ICN Biomedicals Inc. (Irvine, CA). Probe Quant G-50
micro column was from Pharmacia Biotech Inc. (Piscataway, NJ). All other
chemicals were molecular biology grade and were from Sigma Chemical Co. or
Fisher Scientific.
2.

Cell Lines

Thymoma cell lines SAKRTLS12.1 (CD4+CD8 ), TB2.1 (CD4 CD8+), and
AKR1 .G.1 (CD4+ CD8+) were originally obtained from Dr. R. Hyman (Salk
Institute, La Jolla, CA).

61

B.

METHODS
1.

General molecular biology methods

a.

Extraction of plasmid DMA

1)-

Minipreps

Plasmid DNA was isolated from bacterial cells for the purpose of
screening large numbers of colonies for a desired clone (Birnboim and Doly,
1979; Ish-Horowicz and Burke, 1981) as follows.
A single bacterial colony from a transformation plate was transferred into
3 ml of LB (Luria-Bertani) medium (1% tryptone, 0.5% yeast extract, 1% sodium
chloride) containing ampicillin 100 pg per ml in a loosely capped 15 ml tube. The
culture was incubated overnight at 37°C with vigorous shaking. One point five
ml of the culture was stored at 4°C while another 1.5 ml of the culture was
transferred into a labeled microcentrifuge tube and centrifuged at 13,000 rpm for
1 min at room temperature in a Baxter Biofuge 13 microcentrifuge (Baxter
Diagnostics Inc. Scientific Products Division, McGaw Park, IL). The supernatant
was discarded and the pellet was resuspended in 100 pi of solution I (50 mM
glucose, 25 mM Tris-HCI, pH 8.0, and 10 mM EDTA, pH 8.0), gently mixed with
200 pi of solution II (0.2 N sodium hydroxide, and 0.1% SDS) by inverting 4
times, kept on ice for 5 min., and then gently mixed with 150 pi of solution III (3
M potassium acetate, pH 4.8) by inverting 4 times and kept on ice for another 5
min. The resulting mixture was centrifuged at 13,000 rpm for 5 min. Four
hundred pi of supernatant was transferred into a fresh tube, mixed with 800 pi of
95% ethanol, kept at room temperature for 5 min, and then centrifuged at 12,000
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rpm for 5 min. The supernatant was discarded, and the pellet was washed with
500 pi of 70% ethanol and dried in a speed vacuum centrifuge. The pellet was
resuspended in 20 pi of TE buffer [10 mM Tris-CI (pH 8.0), 1mM EDTA (pH 8.0)]
with RNase at 1 pg/pl, and incubated at 37°C for 1 hr.
2).

Wizard™ Plus minipreps DNA purification

The following method was used to isolate and purify plasmid DNA for
automated fluorescent DNA sequencing (Promega Corporation). Three ml of
cells were pelleted by centrifugation for 1 min. at 10,000 x g in a microcentrifuge.
The supernatant was discarded and the tube was blotted upside-down on a
paper towel to remove excess media. The pellet was resuspended completely in
200 pi of cell resuspension solution. The cell suspension was mixed with 200 pi
of cell lysis solution and the tube was inverted 4 times. Two hundred pi of
neutralization solution was added and the tube was inverted 4 times. The lysate
was then centrifuged at 10,000 x gin a microcentrifuge for 5 min. Meanwhile
one Wizard™ Miniprep column was prepared. One of the syringe barrels was
attached to the Luer-LokR extension of the minicolumn, and the tip of the
minicolumn/syringe barrel assembly was inserted into the vacuum manifold, with
the stopcock closed. One ml of the resuspended resin was pipetted into the
barrel of the minicolumn/syringe assembly, and all of the cleared supernatant
was carefully removed from the miniprep and transferred into the barrel of the
minicolumn/Syringe assembly containing the resin. The stopcock was opened
and a vacuum was applied to pull the resin/lysate mix into the minicolumn.
When all of the sample had completely passed through the column, the vacuum
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was broken at the source. Two ml of the column wash solution was added (after
the addition of ethanol) to the syringe barrel and the vacuum was reapplied to
draw the solution through the minicolumn. The resin was dried by continuously
drawing a vacuum for 30 s after the solution had been pulled through the
column. The syringe barrel was then removed and the minicolumn was
transferred to a 1.5 ml microcentrifuge tube and centrifuged at 10,000 x gfor 2
min to remove any residual column wash solution. The minicolumn was then
transferred to a new microcentrifuge tube and 50 pi of water was applied to it.
After 1 min, the tube containing the minicolumn was centrifuged at 10,000 x g in
a microcentrifuge for 20 s to elute the DNA. The minicolumn was removed and
discarded, and the plasmid DNA was stored in the microcentrifuge tube at 4°C.
3).

QIAGEN Max-Preparation

The Qiagen plasmid purification procedure (QIAGEN Inc.), was used to
isolate and purify plasmid DNA for T cell transfection. The following procedure is
for the QIAGEN-tip 500.
Bacterial cells were grown overnight in 500 ml of LB. When the cells
reached A600 = 1.0 to 1.5 they were harvested by centrifugation at 4°C for 15 min
at 6000 rpm in a Sorvall GSA rotor. The pellet was resuspended in 10 ml of
buffer P1 [100 pg/ml RNase A, 50 mM Tris (pH 8.0), 10 mM EDTA (pH 8.0)].
This was followed by adding 10 ml of buffer P2 (200 mM NaOH, 1% SDS). The
suspension was mixed gently by inverting 6 times and incubated at room
temperature for 5 min, after which 10 ml of chilled buffer P3 (3.0 M potassium
acetate, pH 5.5) was added. The solution was mixed immediately, but gently, by
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inverting the tube 6 times. After incubated on ice for 20 min, the samples were
centrifuged at 4°C for 30 min, at 16,000 rpm in a Sorvall SS-34 rotor (Dupont
Co., Newtown, CT). The supernatant was transferred to a new centrifuge tube
and centrifuged for 15 min. Then the supernatant was loaded onto a
QIAGEN-tip 500 which had been equilibrated with 10 ml of QBT (750 mM NaCI
50 mM MOPS [ 3-(A/-morphlino)propanesulfonic acid], pH 7.0, 15% ethanol,
0.15% triton X-100). The QIAGEN-tip was washed twice with 30 ml buffer QC
[1.0 M NaCI, 50 mM MOPS (pH 7.0), 15% isopropanol], then the DNA was
eluted from the column with 15 ml buffer OF [1.25 M NaCI, 50 mM Tris (pH 8.5)
15% isopropnol]. The DNA was precipitated with 0.7 volumes of isopropanol
mixed and centrifuged at 4°C and 10,000 rpm in a Sorvall HB-4 rotor (Dupont
Co.) for 30 min. The supernatant was carefully removed and the pellet was
washed with 15 ml of cold 70% ethanol, air dried, and resuspended in sterile
dH20. Typical yield was 300 to 500 pg of plasmid DNA.
b.

Preparation of Competent Cells

This method was used to make competent cells simply and efficiently
(Inoue et al,. 1990). The stock DH5a cells were thawed. Cells were streaked on
an LB agar plate (1% tryptone, 0.5% yeast extract, 1% NaCI, 1.5% agar, pH at
7.0), incubated overnight at 37°C. The DH5a cells were inoculated in 250 ml of
SOB medium (2% tryptone, 0.5% yeast extract, 10 mM NaCI, 2.5 mM KCI, 10
mM MgCI2, 10 mM MgSOJ. Cells were grown at room temperature with vigorous
shaking until A600 reached 1.0, then cells were kept on ice for 10 min. The
cultural cells were transferred to a 500 ml centrifugation bottle and centrifuged at
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2,500 x g for 10 min. at 4 °C. The pellet was resuspended in 80 ml of ice cold TB
(10 mM PIPES [pperazine-A/,/V-bis(2-ethanesulfonic acid)], 55 mM MnCI2, 15
mM CaCI2, 250 mM KCI, pH adjusted to 6.7 with KOH, sterilized by filtration
through 0.45 pm filter and kept at 4°C) incubated on ice for 10 min then spun
down as before. The pelleted cells were then gently resuspended in 20 ml of
TB. Filtered DMSO (dimethyl sulfoxide) was added to the resuspend cells slowly
with gentle swirling to a final concentration of 7%. The mixture was incubated on
ice for 10 min, and then dispensed into Eppendorf tubes (100 pi each) and
frozen by immersion in liquid nitrogen.
c.

Transformation Procedure

This transformation method is based on the precedure described by
Sambrook, et al., (1989). Fifty ng of plasmid DNA, 1 ng bluescript (as positive
control) and 1 pi of dH20 (as negative control) were added into three different
polystyrene tubes. These tubes were put on ice until used for transformation.
The competent cells were thawed quickly, and transferred into these polystyrene
tubes, incubated on ice for 30 min, and then heated at 42 °C for 1 min. Nine
hundred pi of SOB medium was added, and the mixtures were incubated in a 37
°C shaker for 1 hr. One hundred and fifty pi, 300 pi and 450 pi of each kind of
mixture were streaked respectively on LB agar plates containing 100 pg/ml of
ampicillin and the plates were incubated at 37 °C overnight.
d.

Restriction enzyme digestion

The restriction enzymes were used according to the manufacturers
instructions. The incubation period is usually between 2 and 4 hr.
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e.

Gel electrophoresis of DNA

Since the sizes of DNAs used in this work were between 500 bp to 13,000
bp, the electrophoresis was carried out at room temperature using 0.8% agarose
in 0.5 x TBE buffer [45 mM Tris-borate, 1 mM EDTA (pH 8.0)]. The applied
voltage was 90 volts.
f.

Geneclean II Kit for DNA Purification

The Geneclean II Kit (Bio 101) was used to purify the desired DNA
fragments from agarose gel. The desired DNA bands were excised from the
agarose gel and transferred to a tube, then mixed with 3 volumes of Nal. The
tube was incubated at 55 °C until the agarose was melted. The glassmilk
suspension was then added to the Nal/DNA solution (5 pi glassmilk for < 5 pg
DNA) and the mixture was incubated at room temperature with gentle shaking for
10 to 15 min. A 1.5 ml microcentrifuge tube was used to centrifuge the mixture
at room temperature and 13,000 rpm for 1 min in order to pellet the glassmilk.
The pellet was then washed 3 times with New Wash followed by centrifugation.
The DNA was eluted with 20 pi sterile dH20 twice by incubation at 55 °C for 10
min and then centrifuged.
g-

QIAEX II Gel Extraction Kit for DNA purification

QIAEX II Gel Extraction Kit is designed to extract and purify desired DNA
fragments from any agarose gel in either TAE or TBE buffer. The desired DNA
bands were excised from the agarose gel and transferred to a tube, then mixed
with 3 volumes of Buffer QX1. The QIAEX II was resuspended by vortexing for
30 s. Ten pi of QIAEX II was added to the tube containing DNA fragments from
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agarose gel. The tube was incubated at 50 °C for 10 min to solubilize the
agarose and bind the DNA. The mixture in the tube was mixed well by vortexing
every 2 min to keepQIAEX II in suspension. The tube was centrifuged at room
temperature and 13,000 rpm for 30 s. The supernatant was removed and the
pellet was then washed by resuspended in 500 pi QX1. The tube was
centrifuged at room temperature and 13,000 rpm for 30 s. The pellet was
washed twice with 500 pi of Buffer PE and air-dried for 15 min. The DNA was
eluted with 20 pi of 10 mM Tris-HCI (pH 8.0) twice by incubation at room
temperature for 5 min and then centrifugation at room temperature and 13,000
rpm for 30 s.
h.

Blunt ending DNA fragments

T4 DNA polymerase catalyzes the synthesis of DNA in the 5' to 3'
direction and also has a 3' to 5‘ exonuclease activity, so it converts both 5' and 3'
DNA overhangs to create a blunt-ended molecule (Sambrook, et al.,1989). In
this work , 10 pi of DNA (5 pg), 3 pi of 1 mM dNTP, 1.5 pi of 10x BSA (Bovine
serum albumin, 10 mg/ml), 6 pi of T4 DNA polymerase (3000 U/ml), and 6.5 pi of
dH20 were mixed and incubated at 37 °C for 30 min.
DNA ligation
The Rapid DNA Ligation Kit can ligate sticky-end or blunt-end DNA
fragments in just 5 min at room temperature (Boehringer Mannheim). Ten pi
DNA in 1x DNA Dilution Buffer was mixed with 10 pi 2xT4 DNA Ligation Buffer,
and then mixed with 1 pi of the T4 DNA ligase. The solution was then incubated
for 5 min at room temperature.
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2.

Making the 3’ deletion series

a.

The pAC4d construct

Plasmid AC4d (pAC4d) (Figure 2. 1), previously constructed in Dr. Sands’
laboratory, consists of 6 fragments: 1) a 3477 bp Nol\-Sal\ fragment (1-3477) (
Hansen, 1995), which contains the CD4 enhancer; 2) a 3714 bp Sal\-Xho\
fragment, (3477-7191), which contains the CD4 promoter and 71 bp of the first
exon of the CD4 gene; 3) a 612 bp Xho\-Pst\ fragment (7191-7803), which
contains the most 5' region of the first intron of the CD4 gene including the splice
donor sequences; 4) a 175 bp Pst\-Sal\ fragment (7803-7978), which contains
175 bp of the most 3' region of the first intron of the CD4 gene, including the
splice acceptor sequence; 5) a 1655 bp Sal\-Asc\ fragment (7978-9633), which
contains the CAT gene of pCAT Basic; 6) a 3165 bp Asc\-Not\ fragment (963312798), containing the ampicillin resistance gene (AmpR) and the origin of
replication of pSL1180.
b.

Making construct pS

1)-

Removing the fragment (No1\-Sma\) which contains another
Bcl\ cutting site.

First, pAC4d was cut with Sma\. Not\ linkers were ligated to the Sma\ site
followed by the digestion with A/ofl to yield sticky-ends. Gene Clean II Kit was
used to retrieve the linear DNA without the 2 kb Not\-Sma\ fragment. The
isolated linear plasmid was resealed by ligation using Rapid Ligation Kit.
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Individual colonies were obtained after transformation into DH5a competent
cells and checked for the proper construct by using the Miniprep procedure and
a restriction enzyme EcoRI digestion. The new construct was named as pS.
The activity of the restriction enzyme Bcl\ is blocked by dam methylation which
occurs in DH5a competent cells but not GM48 competent cells. Therefore, pS
was transformed into GM48 competent cells. Minipreps were used to obtain
constructs from the transformed GM48 cells and the construct was checked
using restriction enzyme EcoRI digestion. One mg of pS was obtained using
Maxi-prep.
2).

Bal31 deletion

Bal31 nuclease (Bal31) is an exonuclease that removes mononucleotides
from 3' and 5’ termini of the two strands of linear DNA. Degradation by Bal31
nuclease is absolutely dependent on the presence of calcium. Therefore, the
reaction can be stopped at different stages by adding EGTA [ethylenebis(oxyethlenitrilo)- tetraacrtic Acid] to yield various lengths of DNA fragments.
In this work, pS was linearized with Apa\ and purified with a
phenokchloroform extraction. One hundred and fifty pg of DNA and 50 pi of 2x
buffer, in a microcentrifuge tube, were put on a heating block at 30 °C. Ten
tubes will be set up on ice, each containing 30 pi of 30 mM EGTA. The timing of
Bal31 deletion was started when 2 pi of Bal31 was added to the 150 pg of DNA
and mixed well. Every min, for 10 min, 1 pi of the mixture was taken and added
to the appropriately labeled tubes containing EGTA. Finally these tubes were
heated at 65 °C for 10 min in order to inactivate the Bal31 nuclease. A further
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purification was accomplished using phenokchloroform extraction. The purified
DNA was precipitated with ethanol. After centrifugation DNA was resuspended
in 20 pi dH20 and 1 pi of the DNA solution was checked on the gel.
After the Bal 31 digestion process completed, the DNA samples were cut with
Bcl\, loaded on an agarose gel (1% agarose in 1x TAB), and purified with the
Gene Clean II Kit. The ends of the purified DNA fragments were blunted with T4
DNA polymerase. The linear DNAs were ligated to make constructs which were
then transformed into DH5a competent cells. Colonies from each sample were
picked and DNA plasmids were extracted from those colonies using the Miniprep procedure. The sizes of DNA plasmids were checked by restriction enzyme
digestion and electrophoresis.
c.

Making constructs used as controls

1).

Making the construct containing the CD4 promoter and the

CD4 enhancer
pS was cut with Apa\ and cleaned up by a phenokchloroform extraction.
The linear DNA was digested with Bcl\ and cleaned up again by a
phenokchloroform extraction. Both ends of pS were blunted with T4 DNA
polymerase and then loaded on a agarose gel and purified by gel purification. A
linear DNA without Apa\-Bcl\ fragment was obtained in this way. This DNA
fragment was ligated and transformed into DH5a cells. This construct was
named pS1.
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2).

Making a control construct containing the CD4 promoter but
without the CD4 enhancer (pS16) and a control construct
without both the CD4 promoter and the CD4 enhancer (pS17)

pAC4d was cut with A/ofl and cleaned up with a phenokchloroform
extraction. Then half of the A/ofl cut DNA was digested with Bcl\. The other half
was digested with Xho\. The same procedure was used to blunt both ends of
these DNA fragments and resulting products were cleaned up by gel purification.
DNA fragments were ligated to make the plasmids and then transformed into
competent DH5a cells. The plasmid with the A/ofl/Bc/l deletion contained the
CD4 promoter and did not contain the CD4 enhancer and was named pS16.
The plasmid with the Not\/Xho\ deletion contained neither the CD4 promoter nor
the CD4 enhancer and was named pS17.
3.

Analysis of constructs

a.

Restriction enzyme digestion

Constructs were digested with Psfl and EcoRI in order to check their size.
Seventen samples from the Bal31 deletion constructs were picked and named
pS2 to pS15. pS1, pS16, and pS17 were the controls.
b.

Automated DNA Sequencing

Sequencing was performed using the PRISM Ready Reaction DyeDeoxy
Terminator Cycle Sequencing Kit (Applied Biosystems, Foster City, CA). The
templates were supplied at a concentration of 0.2 pg/ul. The reaction
components (9.5 pi terminator premix, 5.0 pi ds DNA template, 3.2 pmol ds DNA
primer) were mixed in a 0.6 ml microcentrifuge tube for a total volume of 20 /A
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The tubes were then placed in a Perkin-Elmer Cetus Model 9600 thermal cycler
(Perkin-Elmer Cetus, Norwalk, CN) and preheated to 96 °C. Thermal cycling
program-2 was performed as follows: rapid thermal ramp to 96 °C, 96 °C for 10
s, rapid thermal ramp to 50 °C, 50 °C for 5 s, rapid thermal ramp to 60 °C, 60 °C
for 4 min. This was done for a total of 25 cycles, followed by a rapid thermal
ramp to 4°C. The samples were then purified using Centri-Sep columns. The
columns were equilibrated with 800 pi of dH20 for at least 30 min prior to use.
After centrifuging the column at 750 x gfor 2 min in order to remove dH20, the
samples were loaded carefully onto the surface of the resin. This was followed
by centrifuging again at 750 x gfor 2 min and collection of the sample into a
sterile 1.5 ml microcentrifuge tube. The samples were then dried in a speed
vacuum centrifuge. Prior to loading on a 6% acrylamide gel, each sample was
resuspended in 4 pi of loading buffer [5 pi deionized formamide, 1 pi 50 mM
EDTA (pH 8.0)], heat denatured at 90 °C for 2 min, and incubated on ice. The
samples were then loaded onto an Applied Biosystems 373A DNA sequencer
(Applied Biosystems) and sequence data of the DNA samples were collected.
The sequencing primer was 50 bp 3' of the Bcl\ site (13796/4279) and had
the sequence 5'>GAG AGC AGC TGT GGT GAT CCC<3'. Applied Biosystem
394 DNA/RNA Sythesizer (Applied Biosystems, Foster city, CA) was used to
synthesize the primer with a yield of 215.3 pmol/pl. The concentration of the
primer was adjusted to 2.0 pmol/pl for DNA sequencing.
Constructs templates were prepared by using Wizard™ Minipreps
(Promega Corp., Madison, Wl).
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The concentration of each sample was adjusted to 0.2 pg/pl for DNA
sequencing.
4.

T cell transfection

a.

Cells and Cell Culture

1)-

Preparation of Culture Media

Complete RPMI media was prepared in 500 ml batches and stored at 4
°C. To make 500 ml complete media, 25 ml of newborn calf serum (heatinactivated at 50 °C for 1 hr), 5 ml of L-Glutamine (200 mM, 29.2mg/ml), and 5
ml of penicillin-streptomycin (5,000 lU/ml and 5,000 pg/ml respectively) were
added to the RPMI before use.
2).

Thawing Cells

A tube containing SAKRTLS12.1 cells was removed from the -70°C
freezer and thawed rapidly at 37 °C. The freezing cell mixture was diluted by
adding room temperature complete media for a total volume of 15 ml. The cell
suspension was then transferred to a sterile 50 ml tube and centrifuged at 1,500
rpm for 4 min. at room temperature in a Beckman TJ-6 tabletop centrifuge
(Beckman Instrument, Inc., Palo Alto, CA). The cell pellet was resuspended in
25 ml of complete media and then transferred to a small flask. Another 25 ml of
complete media was added to the flask and cells were grown at 37 °C overnight.
On the following day, cell viability was determined and the cells were
subcultured by diluting one fold per day.
3).

Cell Growth and Maintenance

The murine thymoma cell line, SAKRTL12.1, was grown in complete
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RPMI media. This SAKRTLS12.1 (CD4+CD8 ) was obtained from Dr. R. Hyman
(Salk Institute, La Jolla, CA). The cells were cultured at 37 °C in a
water-saturated atmosphere with 5% C02.
4).

Cell Count and Viability

Total cell count and viability determination were done by using a
Neubauer hemocytometer (Fisher Scientific, Fair Lawn, NJ) and a PhotoZoom
Inverted Microscope (Cambridge Instruments). For total cell count, 10 pi of the
cells from a culture flask were loaded onto the hemocytometer. The cells were
counted for each of 5 grids and the total number of cells (N) was calculated as:
N = (average number of cells per grids in 5 grids) x 104 x total volume.
Viability determination was done in a similar manner using the dye
exclusion test. Ten pi of cells was mixed with an equal volume of trypan blue
(0.4% in dH20, filtered through 0.45 pm filter), and left for 1 to 2 min. Ten pi of
cells/trypan blue mixture was loaded onto the hemocytometer and the total
number of non-stained (live) and stained (dead) cells were counted respectively.
Percent viability (V) was calculated as: V = (Number of non-stained cells/Total
number of cells) x 100.
b.

Flowcytometry Activated Cell Sorting (FACs)

Cells were collected by centrifugation for 5 min at 2000 rpm and washed
once with cold 1X PBS. Cell suspension was adjusted to 1 X 107 cells/ml in
diluent [0.01 M PBS (pH 7.4), 1% BSA, 0.1% NaN3). To each of three 15 ml
centrifuge tubes, 100 pi of cell suspension was added first. Then 8 pi of diluent
4 pi of anti-CD4 and 4 pi of anti-CD8 antibody, 4 pi of anti-CD2a (FITC) and 4
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pi anti-CD2a (PE) nonspecific antibody were added respectively into one of the
three tubes containing the cells. The cells were incubated on ice for 30 min.
This was followed by washing the cells with 2 ml of cold diluent and pelleting the
cells by centrifugation at 1200 rpm for 10 min. This washing procedure was
repeated twice. The cells were then resuspended in 0.5 ml diluent for FACs
analyzing using BECTON/ DICKINSON Lysis II Ver 1.1. The experiment
involving these conjugated antibodies was performed in subdued light, and the
tubes containing the solutions were covered with aluminum foil.
c.

Growth Curve

SAKRTLS12.1 cells were grown with a starting density of 8 x 104 cells/ml.
The living cells were counted every 12 hr. A growth curve was obtained by
plotting cell density versus time.
d.

Killing curve of SAKRTLS12.1 cell line

A killing curve was done in order to find out the appropriate voltage
providing high transfection efficiency. Cells were harvested at the density of
2x106 cells/ml, spun down at 1000 x g, and then resuspended at 2x107 cells/ml.
Each electroporation cuvette was added with 100 pi of cell suspension (about
2x106 cells) and then incubated on ice for 5 min. Samples were electroporated
using a Gene Pulser (BioRad Laboratories, Hercules, CA) at the voltage of 200,
210, 220, 230, 240, 250, 260, 270, 280, 290 and 300 volts with the capacitance
extender (BioRad Laboratories, Hercules,CA) was set at 500 pF. Duplicates
were done for each voltage, and three samples not electroporated were used as
controls. After electroporation, samples were incubated on ice for another 5
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min, then diluted 10 fold. The number of living cells in each sample was
counted, and this number was divided by the mean of the control living cell
numbers to yield the percentage of living cells. A killing curve was obtained by
plotting voltages against the percentage of living cells. Cells harvested at 6x105
cells/ml and 1x106 cells/ml before electroporation were treated similarly and two
more killing curves were obtained.
e.

Transient Transfection

Cells were fed 24 hr prior to transfection when they were in the log phase
of the growth curve. Transfection was then performed by harvesting 3.2 x 101
cells and resuspending them in 8 ml of RPMI without additives (serum,
glutamine, penicillin, streptomycin). Each recombinant DNA construct was
transfected triplicately in one assayed. An aliquot of 100 pi of these cells, 4 x 106
cells, was mixed with 7 x 10'12 moles of supercoiled DNA construct and
incubated on ice for 5 min. These cells were electroporated using a Gene Pulser
unit (BioRad Laboratories, Hercules, CA) set at 230 volts and a Capacitance
Extender (BioRad Laboratories, Hercules, CA) set at 500 pF. The Gene Pulser
Unit was put inside the hood to achieve sterile conditions and to save time which
is important for the survival of the cells during the transfection procedure. The
electroporation was followed by incubation on ice for another 5 min. The cells
were then transferred to 3 ml of complete RPMI and incubated at 37°C in a C02
(5%) incubator for 48 hr.
5.

CAT Assays

Chloramphenicol acetyltransferase (CAT) assays were performed as
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described below (Seed and Sheen, 1988; Promega, 1994). After the 48 hr
incubation, the cells were harvested, washed with PBS, resuspended in 100 pi
of 1x Reporter Lysis Buffer (Promega Corp., Madison, Wl). Mixtures were
incubated for 15 min at 4°C, and then centrifuged at 13,000 rpm for 3 min. The
supernatant containing cellular extract was transferred to a new tube and heat
inactivated at 60°C for 10 min. Then 90 pi of cellular extract was mixed with 5 pi
n-butyryl coenzyme A (5 mg/ml), 24 pi dH20, and 0.6 pi 14C-chloramphenicol
(0.025 mC/ml). The reaction mixture was incubated at 37 °C overnight. The
reaction products were extracted once with 300 pi xylene and back-extracted
twice with 100 pi 0.25 M Tris-HCI pH 8.0. The final sample was mixed with 10 ml
scintillation cocktail and the radioactivity was counted using a Beckman LS3801
Liquid Scintillation System (Beckman Instruments, Inc., Polo Alto, CA).
6.

Making the 5’ deletion series

Construct pAC4d was linearized with Smal\ followed by a phenolchloroform clean up. Bal 31 deletion assays were performed followed by phenolchloroform clean up. The ends of the DMA fragments were blunted with T4 DNA
polymerase followed by a phenol-chloroform clean up. Not\ linkers were ligated
using T4 DNA ligase and then linearized with Not\. These fragments were
further purified using the Geneclean II kit. Sticky ends were ligated using T4
DNA ligase and transformed into DH5a competent cells. Constructs were
obtained by minipeps and screened by EcoR\/Sal\ digestion. Selected
constructs, later confirmed by automated DNA sequencing, were transformed
into GM48 competent cells. Minipreps were used to obtain constructs from the
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transformed GM48 cells. These constructs, checked by restriction enzyme
digestion, were digested with Apa\ and then with Bcl\. The ends of the double
stranded DNA were blunted with T4 DNA polymerase. The desired fragments
were purified by Geneclean II gel purification and self-ligated with T4 DNA ligase.
These constructs were then transformed into DH5a competent cells. Mini-preps
EcoR\/Sal\ digestion and electrophoresis were used to select out the colonies.
Selected constructs were obtained using the Qiagen Maxiprep Kit, then checked
with EcoR\/Sal\ digestion and electrophoresis. These 5' deletion series were
transfected into SAKRTLS12.1 cells and CAT assays were performed as
described above.
7.

Making constructs containing the functional fragment at
different locations and orientations relative to the CD4
promoter

a.

p900 Construct

The construct p900 (Figure 2. 2) was made previously in Dr. Sands’
laboratory. The p900 is the construct which consists of the murine CD4
promoter region and pCAT basic vector. In the p900 construct, the CD4
promoter region is located immediately upstream of the CAT reporter gene.
Therefore, the CAT reporter gene is driven by the CD4 promoter.
b.

Subcloning the functional DNA fragment at different locations
and orientations relative to the CD4 promoter

A 364 bp functional DNA fragment (named as S-a) was generated by
EcoR\/Not\ double digestion of the construct S13 (S13 is the construct made by
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31 deletion) followed by the gel purification method previously described. This
fragment was inserted into: 1) p900 at the H/ndlll site located upstream of the
promoter region; 2) p900 at the Asc\ site located downstream of promoter region
(Figure 2. 3). These constructs were screened by PvuW digestion. The
orientations of the inserted fragment were determined by Bgl\\/Nhe\ double
digestion for the insertion upstream of the promoter and by Bgl\/Nhe\\ double
digestion for the insertion downstream of the promoter.
A 292 bp functional DNA fragment (named as S-b) was obtained by
BamH\/Not\ double digestion of the construct S3 (S3 is the construct made by 3'
deletion) followed by gel purification method. This fragment was inserted into:
1) p900 at the H/ndlll site; 2) p900 at the AscI site. These constructs were
screened by PvuW digestion. The orientations of the inserted fragment were
determined by PvuW digestion.
These constructs, containing the functional DNA fragment (S-a or S-b) at
different locations and orientations relative to the CD4 promoter, were further
analyzed by performing transient transfection and CAT assays.
8.

Nuclear protein extraction

Nuclear extracts from different T cell lines were prepared as follows. Cells
were harvested at the late log phase. They were washed once with 5 volumes of
cold PBS and once with 5 volumes of ice-cold Buffer A [10 mM HERBS (pH 7.9)
1.5 mM MgCI2, 10 mM KCI, 0.5 mM DTT (dithiothreitol)]. The cells were then
resuspended in 2 volumes of ice-cold Buffer A and lysed using 10 strokes of a
type B glass pipette pestle and a Bounce homogenizer.

84

0

sz
o

0

£ §
O >

0

>

_0
0
0
c

o

0
c
_0

o
TJ
c
TO
0
c

o

TO
o

o

C
0
0

H=
■D
TO

w
c

0

2i

to ^

i 0
O in

■O

o
m
0
TO 0
O
o x:
10

0

.-t± o
0 0
_ .in

O 0
0

^ =
"O
0
•S
3:
"O

c 0
TO JZ
c o

o

C

CD —
0 -Q
0
0 0
O 0

E

P 0
Q. TO

E
U)
TO

<

z

Q
TO
C

Q c
O 0
0 E
5 CD
TO
^
o 4=

<
E z
TO

0

o

£ E! o

o
c
3

m ® £
CL E o
=5 -»—*
-0
QCO O
.

0
CD
C
c

o
o

J2
3

§0^0
o°
0 I— S

.in

0 cf -2
= .9 ^

-o CD .>
■S 0 _TO
0
0 ^ ^
: O _c o 0
E c
CN 0-0°

00 E

S2 ao o-iS
,5> O ^ Q -2
Ll O ^ O o
85

c

0

E

CD
0
CM
CM
CM

-O

c

CC

a
E

<
0
O

o

E

§1
05 15

LO
CO
lO

O

Q.

O
CL

lo.

a
o
h<

o
m

<

z

Q

86

zz

z

<
D

The nuclei were pelleted at 3,300-4000 rpm for 10 min and resuspended in 3 ml
of Buffer C [20 mM HERBS (pH 7.9), 25% glycerol, 0.42 M KCI, 1.5 mM MgCI2,
0.2 mM EDTA, 0.5 mM PMSF (phenylmethyl-sulfonyl fluoride), 0.5 mM DTT].
Salt concentration was adjusted to 0.4 M KCI by the addition of 2.5 M KCI. The
nuclei were lysed using a type A glass pipette pestle with the Dounce
homogenizer. The broken nuclei were transferred to an ultracentrifuge tube and
shaken for 30 min at 4°C, followed by centrifugation at 15,000 rpm for 30 min.
The supernatant was dialyzed against 50 volumes of Buffer D [20 mM HEPES (
pH 7.9), 20% glycerol, 0.1 M KCI, 0.2 mM EDTA, 0.5 mM PMSF, 0.5 mM DTT]
for 5 hr at 4°C. The dialyzed extracts were then centrifuged at 20,000 rpm for 30
min at 4°C. The supernatant was divided into 100 pi aliquots and stored at -70
°C. The concentration of protein in the nuclear extracts was determined using
the Bradford method (Bio-Rad protein assay kit).

9.

Dephosphorylation and End-labeling the functional fragments

The procedure used to label the 5' ends of DNA fragments in the
electrophoretic mobility shift assay (EMSA) was described previously (Maniatis et
al., 1989).
a.

Dephosphorylation

This reaction was performed to remove the 5' terminal phosphate from
DNA fragments prior to labeling with [y-32P]ATP and T4 polynucleotide kinase.
The following was added to 1 to 20 pmol of DNA termini: 1 pi calf intestine
phosphatase (1,000 U/ml), 2 pi 10 X phosphate buffer [1 X concentration: 50
mM Tris-HCI (pH 9.3), 1mM MgCI2, 0.1 mM ZnCI2, 1 mM spermidine), and sterile
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dH20 for a final volume of 20 pi. The reaction mixture was incubated at 37 °C for
2 hours and stopped by phenol-chloroform extraction. This was followed by
precipitating the dephosphorylated DNA with 1/10 volume of 3 M NaOAc (pH
5.2) and 2 volumes of 95% ethanol overnight at -20 °C. The sample was
centrifuged for 15 minutes at 13,000 rpm, washed once with 70% ethanol, and
resuspended in 20 pi of dH20.

b.

Labeling the 5' ends

The concentration of the dephosphorylated DNA fragment was adjusted
to about 50 ng/pl. One pi of DNA fragment was mixed with 3 pi 10x kinase
buffer, 1 pi T4 kinase, 1 pi 32P ATP (7,000 Ci/mmol; 0.167 mCi/ pi), and 24 pi
H20 at 37°C for 1 hr. The reaction was stopped by adding 20 pi H20 and 2 pi
0.5 M EDTA (pH 8.0). DNA fragments were cleaned up using phenol-chloroform
extraction. These DNA fragments were then resuspended in 125 pi cold ethanol
with 1 pi tRNA (20 mg/ml) and 1 pi 1.5 M NaCI. This solution was incubated at
-70 °C for 15 min or -20 °C for 2 hr (or overnight). After incubation, the solution
was spun down at 13,000 rpm for 15 min in a microcentrifuge. The supernatant
was discarded as radiation waste. DNA fragments were resuspend in 50 pi of
TE. Labeled DNA fragments were purified as follows: the labeled reaction
mixture loaded on a G50 column, centrifuged at 800 rpm for 2 min, and washed
by the addition of 50 pi of TE. One pi of labeled DNA fragments was taken and
mixed with 10 ml of scintillation fluid and counted in a Beckman LS3801 Liquid
Scintillation System. Another 1 pi of labeled DNA fragments was loaded on a
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4% polyacrylamide gel followed by autoradiography to check the purity of the
radioactive fragment.
The functional DNA fragments (S-a and S-b) were 5' labeled as described
above.
10.

Electrophoretic mobility shift assay (EMSA)

Three hundred ng of nuclear protein was added to the tube containing 1 pi
of 1 mg/ml poly dldC and 20 pi of the 1X AS buffer [10% glycerol, 0.5 mM EDTA,
1 mM DTT, 20 mM HEPES (pH 7.9), 50 mM KCL, 2 mM MgCIJ and incubated
on ice for 10 min. One pi of end-labeled double-stranded DNA fragments
(15,000 cpm/pl), also called probe here, was added to this tube and the reaction
mixture was incubated at room temperature for 20 min. The reaction mixture
was electrophoresed through a 4% acrylamide gel at 120 volts for 3 hr. The gel
was dried and exposed to a Fuji RX X-ray film (Fisher Scientific) with an
intensifying screen at -80 °C for 12 hr.
For competition EMSA experiments, specific or nonspecific DNA
fragments (50 to 200 folds over probe) were incubated in the reaction mixture
prior to addition of the nuclear extracts.
The interactions between the functional DNA fragment (S-a or S-b) and
each of several nuclear extracts from SAKRTLS12.1, TB2.1 and AKR1.G.1 were
identified by EMSA, and the specificity of the interactions was determined by the
competition assay.
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11.

Locating binding sites within the silencer by the DNase I
footprint technique

DNase I footprinting is a technique used to study the sequence-specific
binding of protein to DNA. This technique can be used to determine the site of
the interaction of most sequence-specific DNA-binding proteins. Therefore, the
DNase I footprinting has been extensively applied to the study of transcription
factors.
a.

Labeling one end by restriction enzyme method

The 364 bp S-a fragment was generated by EcoR\/Not\ double digestion
of the construct S13 followed by gel purification method described before.
Vector pGEM-11Zf(+) (Figure 2. 4) was opened by EcoR\/Not\ double digestion
followed by gel purification. The fragments S-a was then subcloned into the
pGEM-11Zf(+) vector at EcoRI/A/ofl sites forming the construct S-A. The
construct S-A was checked by EcoR\/Not\ double digestion and Bag\/Hind\\\
double digestion. A 389 bp fragment was generated by Bag\/Hind\\\ double
digestion of the construct S-A followed by gel purification. This 389 bp fragment,
named S-a’, contains the S-a fragment. The S-a’ fragments were end- labeled
with 32P ATP and T4 polynucleotide kinase as described before. Therefore, the
singly 5' end labeled fragments can be obtained from the labeled S-a’ fragments
by Not\ digestion followed by purification using Probe Quant G-50 micro column
to remove the 3' end label. Alternatively, the singly 3' end labeled fragments can
be obtained from the labeled S-a’ fragments by EcoRI digestion followed by
purification using Probe Quant G-50 micro column to remove the 5' end label.
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The vector pGEM-11Zf(+) was opened by BamHI/A/ofl double digestion followed
by gel purification. The fragments S-b was then subcloned into the pGEM11Zf(+) vector at BamH\/Not\ sites forming the construct S-B. The construct S-B
was checked by BamH\/No1\ double digestion and EcoRI/H/nc/lll double
digestion. A 323 bp fragment was generated by EcoRI/H/nc/lll double digestion
of the construct S-B followed by gel purification. This 323 bp fragment, named Sb’, contains the S-b fragment. The S-b’ fragments were end- labeled with 32P
ATP and T4 polynucleotide kinase as described before. Therefore, the singly 5'
end labeled fragments can be obtained from the labeled S-b’ fragments by Not\
digestion followed by purification using the Probe Quant G-50 micro column to
remove the 3' end label. Alternatively, the singly 3' end labeled fragments can
be obtained from the labeled S-b’ fragments by BamH\ digestion followed by
purification using the Probe Quant G-50 micro column to remove the 5‘ end
label.
b.

Preparing the sequence ladder (G+A)

A sequence ladder (G+A) was prepared as described previously (Maxam,
A. and Gilbert, W. 1980). Each singly end-labeled probe was resuspened in 10
pi dH2Q (200,000 cpm) followed by addition of 25 pi of formic acid and then
incubated at room temperature for 5 min. The reaction was stopped by adding
200 pi of hydrazine stop buffer [0.3 M sodium acetate (pH 7.0), 1.0 mM EDTA,
and 25 pg/ml tRNA], 750 pi 100% ethanol (-20°C ), and immersing in a bath of
dry ice/ethanol for 5 min. DMA was collected by centrifuging 5 min at 15,000 x g,
then was rinsed twice with 70% ethanol and drained. Any remaining reagent was
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removed by reprecipitation. The reprecipitation was done by adding 200 pi
dH20, 20 pi 3 M sodium acetate, and 500 pi 100% ethanol to the DNA, mixing
well and immersing in a bath of dry ice/ethanol for 5 min followed by
centrifugation and drying in a speed vacuum. Seventy pi of 10% piperidine was
added, mixed with DNA and incubated at 90 °C for 30 min. The piperidine was
removed by drying under vacuum. The traces of piperidine were further
removed by evaperating the sample twice from 30 pi dH20. The DNA ladder
was resuspended in 6 pi loading buffer (80% formamide, 10 mM NaOH, 1 mM
EDTA, 0.1%Xylene Cyanol, 0.1% Bromphenol Blue).
c.

DNase I Footprinting Analysis

The Core Footprinting system (Promega, Madison, Wl) was used to
identify transcription factor binding sites. Briefly, singly 32P end-labeled DNA
probe was generated as described above. Tubes were set up and each of them
contained 1 pi of poly(dl-dC) (1 mg/ml) and 100 pi of binding buffer [10%
glycerol, 10 mM HEPES-NaOH (pH 7.9), 4 mM Tris-HCI (pH 7.9), 40 mM NaCI, 1
mM EDTA, 1 mM DTT, 300 mg/ml BSA]. One pi 32P-labeled DNA probe (50,000
cpm/ml) was added to each tube and mixed well. This was followed by adding 60
pg of SAKR nuclear extract into the binding buffer. The reaction was mixed well
and incubated at room temperature for 30 min. Then 50 pi of the cofactor
solution (10 mM MgCI2, 5 mM CaCI2) was added into reaction mixture and
incubated at room temperature for 1 min. After the 1 min incubation, different
amounts of DNase I (0.1 u/pl), 3 pi and 6 pi, were added separately to the
different tubes which containing the probe but without SAKR nuclear extract.
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Also different amounts of DNase I (1u/|jl), 3 [i\, 6 pi and 9 pi , were added
separately to the different tubes which containing both probe and SAKR nuclear
extract. After 1 min incubation at room temperature, the reactions were
terminated by adding 150 pi of stop solution (200 mM NaCI, 30 mM EDTA, 1%
SDS, and 100 pl/ml tRNA). DNA fragments were extracted with
phenol:chloroform:isoamyl alcohol. The DNA in the top phase was precipitated
with 2 volumes of cold ethanol at -20 °C for 2 hr. The pellets were collected by
centrifugation at 13,000 rpm for 15 min at 4 °C and washed once with 80 %
ethanol. The DNA fragments from each sample were then dried under speed
vacuum and resuspended in 4 pi of the loading buffer. The DNA fragments,
resuspended in the loading buffer, were heated at 95 °C for 2 min followed by
incubation on ice for 2 min. They were then loaded on a 6% polyacrylamide
sequencing gel. The gel was run at 1500 V, 60 watts in 1 X TBE buffer until the
bromophenol blue reached the bottom. The gel was dried at 80 °C for 1 hr and
exposed to a Fuji RX X-ray film (Fisher Scientific,) with an intensifying screen at 80 °C for 20 hr.
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CHAPTER THREE
III. ANALYSIS OF THE CD4 ENHANCER REGION FROM THE 3' DELETION
SERIES

A.

RESULTS
1.

Explanation of constructs (Fig. 3.1)

a.

pAC4d

Plasmid AC4d (pAC4d) consists of 6 fragments: a) a 3477 bp Not\-Sal\
fragment, (1-3477), which contains the CD4 minimal enhancer; b) a 3714 bp Sal\Xho\ fragment, (3477-7191), which contains the CD4 promoter and 71 bp of the
first exon of the CD4 gene; c) a 612 bp Xho\-Pst\ fragment, (7191-7803), which
contains the most 5' region of the first intron of the CD4 gene including the splice
donor sequences; d) a 175 bp Psfl-Sa/I fragment, (7803-7978), which contains
175 bp of the most 3‘ region of the first intron of the CD4 gene, including the splice
acceptor sequence); e) a 1655 bp Sal\-Asc\ fragment, (7978-9633), which
contains the CAT gene of pCAT Basic (Promega, Madison, Wl); f) a 3165 bp
Asc\-Not\ fragment, (9633-12798), containing the ampicillin resistance (AmpR) and
the origin of replication of pSL1180 (Pharmacia Biotech Inc. Piscataway, NJ).
b.

Plasmid S (pS)

pS is a deletion product of pAC4d. pS does not contain a 2078 bp Not\Sma\ region, (1-2078), present in pAC4d. The rest of pS is the same as pAC4d.
The size of pS is 10,729 bp.
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Figure 3.1. Composition of constructs pAC4d, pS, pS1, pS16 and pS17. pS
is identical to pAC4d except for a deletion of a 2078 bp Not\-Sma\ region, (12078), present in pAC4d. pS16 and pS17 are the deletion products of pS. pS16
lacks a 4279 bp Not\-Bcl\ region, (1-4279) and thus does not contain the 5'
enhancer but does contain the CD4 promoter. pS17 lacks a 5122 bp Not\-Xho\
fragment, (1-5122). pS17 does not contain either the 5' enhancer or the CD4
promoter.
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c.

Plasmid S1 (pS1)

pS1 is a deletion product of pS. pS1 was created by deleting a 3,117 bp
Apa\-Bcl\ fragment, (1162-4279), and then blunting the resulting deleted plasmid
with 14 DNA polymerase and ligating the blunted ends together. The size of pS1
is 7,616 bp and pS1 contains both the CD4 enhancer and the CD4 promoter.
d.

Plasmid S16 (pS16)

pS16 is a deletion product of pS. pS16 does not contain a 4279 bp A/oflBcl\ fragment, (1-4279). pS16 does not contain the CD4 enhancer, but does
contain the CD4 promoter. The size of pS16 is 6,450 bp.
e.

Plasmid S17(pS17)

pS17 is a deletion product of pS. pS17 does not contain a 5122 bp Not\Xho\ fragment, (1-5122), and therefore it does not contain either the CD4
enhancer or the CD4 promoter. The size of pS17 is 5607 bp.
f.

Bal31 deletion series (Fig. 3.2)

The deletion series was obtained by using Bal31 nuclease to delete DNA
sequences between an Apa\ site, positioned at 3236 in pAC4d, and a Sma\ site,
positioned 5' of the Apa\ site at 2078 in pAC4d. The Bal31 deletions all start from
the Apa\ site and stop at different points 5' of the Apa\ site. All the Bal31 deletions
are fused at a blunted Bcl\ site in such a way to make the 3' region of each
deletion construct identical, each containing the pAC4d sequences
between 4279 bp and 12,798 bp.
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Figure 3.2. The Bal31 deletion series. Each deletion construct, pS1 to pS15,
does not contain a 3117 bp Apa\-Bcl\ fragment (1162- 4279) that is present in
pS. pS1 is a construct without any Bal31 deletion. The number following each
plasmid construct indicates the location of the end point of the Bal31 deletion in
that construct. For example, S2-1027 means that the end point of the Bal31
deletion in pS2 is at 1027 bp 3' of the A/ofl site. The DNA 3' of each deletion is
identical. Each deletion has been blunted with T4 DNA polymerase and fused to
a T4 DNA polymerase blunted Bcl\ site located at position 4279 in pS.
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AscI (7564)

2.

Relative positions of deletion ends comparing with CD4
minimum enhancer, CD4-1, CD4-2, CD4-3 and human homology
region.

The murine CD4 minimal enhancer is a 339 bp fragment (Sawada and
Littman, 1991). This enhancer element is located at nucleotide position 568 to
907 in pS1. There are three protein binding regions within the minimal enhancer,
CD4-1, CD4-2 and CD4-3 (Sawada et al., 1995). The locations of these regions in
pS1 are: CD4-1 (548-606); CD4-2 (634-651); and CD4-3 (766-780).
There are 11 regions within the 1166 bp 5' of the Apa\ site, positioned at
nucleotide 1166 in pS1, that have homology to the human CD4 enhancer
(Hansen, 1995; Blum et al., 1993) (Fig. 3.3 and Fig. 3.4). Four of these
homologous regions, regions 1-4, are located 5' of murine CD4 minimal enhancer.
All the positions shown in parenthesis are relative to nucleotide sequence found in
pS1 with position 1 corresponding to the Sma\ site found in pAC4d at nucleotide
2078 which has been converted to a Not\ site in pS1.

Region 1 (149-204) has

75% homology. Region 2 (263-289) has 81% homology. Region 3 (381-431) has
71% homology. Region 4 (500-528) has 69% homology. Six of the regions
having homology to the human enhancer, regions 5-10, are located within the
murine CD4 minimal enhancer. Region 5 (550-581) has 66% homology. Region
6 (587-608) has 91% homology. Region 7 (612-638) has 74% homology. Region
8 (694-721) has 72% homology.
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Figure 3.3. DNA sequence from the A/ofl site (1) to the Sail site (1409). The
sequence region underlined is the murine CD4 minimal enhancer. Red color
sequence regions represent human homology regions (Hhr). Regions double
underlined are the murine CD4 regions 1-3 (CD4-1, CD4-2, CD4-3) that bind to
trans-acting factors. The arrows indicate the location of the end of the Bal31
deletion in each construct.
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1 GGCCGCAAGG GTTGAGGAAT TGTCTCTGA ACAGGCTCGC

41 TCACTTGGTC GAGGGCCAGA GGCCTCAGTT CTTCCTCTTT
VS 15(87)
81 AGTGCCATGG CAACTGGCCT CTCTGTGGAC AGGATGGATG

V SI 4(142)
121 AGACAAAAGC ACTCAGGCGT CATCACCT GA TCTTGAAAGT

161 GATAGGTCAT CATTTCTGCC CCTGTCTGTA GATCACACAG
Hhr1
201 GCCA CTTGTG ACAGGGTATA GGAAATGCAA, GATAAGGATG

241 TCAACCAAGG AAGGGGATTG CT GGGACCTC TTAGAGCCTG
Hhr2
281 GCTGTCACA A GCTAGCAGTA CTTGAATGAC AGACAGCCCA

321 AGAAAGAGGA GGGGGCATCT CTGATTATCC GACATCTGTG
VS13(364)
361 CCCTTCTCAC GGAATTGGCA GG CTCCTCCA CTGTCAACTT

V SI2(420)
401 TGCAGAAGTT CTGGAGGCTA ATCAAGGCCAA TCCTGCAGG
Hhr3
VS11(465)
441 TAGAAGGCTA CCCGGTGGAC CTCCAGACCC TTGGCTACTG

481 CTCCTTCCAC ATATGAACT T GTTTACAGGG CTTCATGGCT
Hhr4
521 CAGAACCT AC CCAGAGAATT TTCTGTTCT A CATCCCCAAC
Hhr5
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T SI0(566)
561 CAAGCCA AGGTGTTGGGGTTC AAATT T GAG CCCCAGCTGT
Hhr6
TS9(606)
601 TAGCCCT CTGC AAAG AAAAA AAAAAAAAAA AAAGAACA AG
CD4-1
Hhr7
TS8(645)
TS7(671)
641 GGGCCTAGATT TCCCTTCTG AGCCCCACCC TAAGATGAAG
CD4-2
661 CCTCTTCTTT CAA GGGAGTG GGGTTGGGGTGGAGGCGGAT
Hhr8
721 C CTGTCAG CT TTGCTCTCTC TGTGGCTGGC AGTTTCTCCA
Hhr9

Y $6(790)
761 AAGGG TAA CAGGTGTCAGCT GGCTGAGCCT AGCTGAACCC
CD4-3
Hhr10
YS5(812)
801 TGAGACATGC TAG CTCTGTC TTGTCATGGC TGGAGGCAGC

841 CTTTGTAAGT CACAGAAAGT AGCTGAGGGG CTCTGGAAAA

861 AAGACAGCCA GGGTGGAGGTAGATTGGTCC TTCTAGT

W $4(936)
921 AGCTTCCAAG GTGCCGCCAGGGT CTGGGCGTTTCACCCCA
Hhr11
961 CACCAAGGAG AAGCCTTTGT AACCCAGCCC AGCTACCGAC

Y $3(1009)

Y $2(1027)

1001 CCAAGCCCAC CCCACAGCTA TTTTGCGGGA GTTTCAGTGC
1041 TATAGCAGAT GGTTTCTGTA ACGAGTCACC ACAGGCTGCA
1081 CCTGGTGCTC CACTTCCATC GTC CTCATCT CTAATACACT

1121 GGCCTCCTCT AGTGCTCTTT TGGCAGCCTC TCACAGTGTC
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▼ S1/Apa\(1162)
1161 CGGGCCCCTG CTTCCTTTCT CCCATTTGGT CACCTTCCCC

1201 TCTTCTAGCT AGAAGCACAG AATATGGACA GCAAACATAG
1241 CTCCAAACAA GAACTAGGAA TCTGCAAAAA TCAGGCTCTA

1281 AGCTCACCTT CAGGGACCGG GGCAGACAGC CTGACTTCAG
1321 TTTCCTTTGT AAAATGAGGA TAGCGAGCTG ACCTCGGTGG

1361 CTCTTGCCTG TAGCCTTCCA ACTCGGAGGC TGAGGCAGGA
W Sal1(1409)
1401 AGAGCTGGTC GACCAGCTCA
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Figure 3.4. Relative positions of the deletion ends compared with the
locations of CD4 enhancer binding element, CD4-1, CD4-2, CD4-3, and the
11 human homology regions. The position of the minimal murine CD4
enhancer (mCD4enh), the protein binding sites, CD4-1, CD4-2, CD4-3, present
within the mCD4enh (CD4r), and the 11 regions that show homology to the
human enhancer (Hhr) are shown as gray boxes beneath the plasmid pS1. The
DNA present in the pS2 to pS15 Bal31 nuclease deletion constructs are show
below the human homology regions. The number following each plasmid
deletion construct indicates the location of the Bal31 deletion end point in that
construct.

107

Notl

Apal(l 162)

SI

mCD4enh

DD

CD4r
Hhr

D

□ 0 □ □□□] □□□

S2-1027
S3-1009
S4--936
S5--812
S6--790
S7-671
S8--645
S9--606
SI 0-566
Sll-456
S12-420
SI3-364
S14-142
SI 5-87

108

o

Region 9 (729-765) has 86% homology. Region 10 (769-813) has 83% homology.
The last region of sequence homology, region 11 (918-943), is 31 of the CD4
minimal enhancer and has 75% homology.
3.

Growth Curve of SAKRTLS12.4 cell line

The growth curve can provide vital information of a cell line, such as: log
phase; the cell population doubling time in the log phase and the maximum cell
density (saturation density). The growth curve of SAKRTLS12.4 cell line was
obtained by plotting cell density (living cells per ml) against time (Fig. 3.5). From
the growth curve of SAKRTLS12.4 cell line, cell density varies from 1.2x106
cells/ml to 3.7x106 cells/ml in the log phase. In the log phase, the cell population
doubling time (e.g. the time it takes to double the cell concentration from 1.5x106
cells/ml to 3.0x106 cells/ml) is approximately 12 hours. The maximum cell density
is approximately 3.96x106 cells/ml.

4.

Killing curve of the SAKRTLS12.4 cell line

The application of a brief high voltage electric pulse to mammalian cells
leads to the formation of nanometer-sized pores in the plasma membrane. DNA
is taken directly into the cell cytoplasm through the pores (Neumann et al.,1982).
When the capacitance extender is set at 500 pF and the voltage is too low, the
plasma membrane of cells are not sufficiently altered to allow the DNA to pass
though. But if the voltage is too high, the cells can not recover from
electroporation and die.
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A killing curve provides information about the relationship between the applied
voltage and the percentage of cells that survival the applied voltage. Usually, the
voltage which causes approximately 50% of the cells to die yields the best
transfection efficiency (Sambrook et al., 1989). The killing curves of
SAKRTLS12.4 cell line were obtained by plotting applied voltage (volt) against
percentage of living cells (Fig 3.6). When cells were harvested at a density of
6.6x105 cells/ml, the voltage which causes 50% cell death is about 250 volts.
When cells were harvested at the density of 1.1x106 cells/ml, the voltage causing
50% cell death is about 230 volts. When cells were harvested at the density of
2.0x106 cells/ml, the voltage causing 50% cell death is about 230 volts.

5.

Results from CAT assay

a.

Minimal Enhancer element is necessary for higher expression
of CAT report gene.

Compared with pS16 (promoter alone), pS1 to pS4, which contain the
complete minimal enhancer fragment, show about 420% to 500% higher CAT
activity indicating that the fragment containing the CD4 minimum enhancer is
capable of significantly stimulating the CD4 promoter to express the CAT reporter
gene at a high level (Fig. 3.7).
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b.

The 219 bp fragment of which the 3' end is located 153 bp
upstream of Apa\ (1126) site appears to have a neutral function
in CAT report gene expression.

The CAT activity obtained from transfecting pS3, pS4, pS5 and pS6 into
SAKRTLS12.1 are not significantly different. This indicates that the 219 bp of
DNA contained within this region does not affect the ability of the CD4 promoter to
express the CAT report gene. Therefore, this 219 bp region appears to have a
neutral function relative to its ability to stimulate or repress the CD4 promoter.
c.

A 145 bp region is essential for the function of CD4 enhancer.

There is a 119 bp fragment (671-709) deleted in pS7 that is present in
pS6. This 119 bp fragment contains CD4-3 and human homology regions 8 and
9. When this 119 bp fragment is deleted, the CAT activity that is observed by
transfecting pS7 drops 57% compared to the CAT activity observed by
transfecting pS6. When an additional 26 bp is deleted in the 5' direction cutting
part of CD4-2, the CAT activity drops by an additional 91%. Therefore, the
presence of this 145 bp DNA region is necessary for the function of CD4 minimal
enhancer.
d.

A 364 bp DNA region (1-364) has a negative effect on the CD4
promoter.

S16 is the construct containing no enhancer but only the promoter. If the
CAT activity value of a construct is significantly lower than that of S16, it indicates
the existence of a negative function. There are no significant differences among
the CAT activity values of pS8 through pS13. But comparing with CAT value of
117

S16, their CAT activity values dropped between 17% (pS8) and 47% (pS10)
indicating the existence of a negative function. The CAT activity values obtained
from transfecting pS14, pS15 and pS16 are not significantly different. When S13
was further deleted corresponding to S14, the negative effects did not exist
anymore. Therefore, a 364 bp DNA fragment corresponding to S13 (1-364) has a
negative effect on the CD4 promoter, showing the function of a silencer. This
364bp DNA region contains two human homology regions (1 and 2).

B.

DISCUSSION
1.

Minimal enhancer is necessary for high expression of the CD4
gene

A minimal enhancer has been localized to a 339 bp region approximately
13 kb 5' of the transcriptional start site of the murine CD4 gene. This minimal
enhancer is T cell-specific but not subclass-specific (Sawada and Littman, 1991).
Studies in transgenic mice have also confirmed the presence of a T cell-specific
enhancer 5' of the CD4 promoter (Blum et al., 1993; Killeen et al., 1993; Hanna et
al., 1994, Salmon et al., 1996). These reports confirm that the 5' T cell-specific
enhancer is indeed capable of stimulating the T cell-specific transcription arising
from the CD4 promoter. Siu et al. (1992) reported that in transient transfection
experiments, the murine CD4 promoter alone functions at high levels of activity in
CD4+CD8'mature T cells but not in CD4+CD8+ immature T cells. In the work
reported in this dissertation , transiently transfected constructs which contain the
minimal enhancer fragment show 420% to 500% higher CAT activity than a
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construct which contains the CD4 promoter alone, indicating that the fragments
containing the CD4 minimum enhancer are capable of significantly stimulating the
expression of the CAT reporter gene (see figure 3.7).
2.

The 219 bp fragment of which the 3' end is located 153 bp
upstream of Apa\ (1126) site appears to have a neutral function
in CD4 gene expression.

The CAT activity values of pS3, pS4, pS5 and pS6 are close to each other.
This indicates that deletion of the 219 bp DNA region, of which the 3' end is
located 153 bp upstream of Apal (1126) site, does not affect CAT report gene
expression. Therefore, this 219 bp fragment containing the human homology
region 11 appears to have a neutral function in CD4 gene expression.
3.

Boundary of the CD4 minimal enhancer

The murine minimal CD4 enhancer has been identified as a 339 bp BsfXIAvaW restriction fragment which is positioned approximately 13 kb 5' of the
transcriptional start site of the CD4 gene (Sawada and Littman, 1991). Sawada
and Littman (1991) also found that the 339 bp fragment had a T cell-specific
enhancer function, but they did not determine the exact boundary of this minimal
enhancer. A comparison of the CAT assay results obtained from transfecting
pS4, pS5 and pS6, which all contain the 5' portion of the 339 bp restriction
fragment, indicate that there is no significant difference among them. pS4
contains the complete CD4 minimal enhancer and human homology region 11.
pS5 contains the 241 bp of the 5' portion of the 339 bp minimal enhancer region
and no human homology region 11. pS6 contains only 219 bp of the 5' portion of
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the minimal enhancer region. The deletion of the 120 bp region of the 339 bp
minimal enhancer region, including the human homology region 11, does not
affect the function of the CD4 enhancer. These data place the 3' boundary of the
minimal enhancer 120 bp 5‘ of the AvaW restriction site present at the 3' of the 339
bp BstX\-Ava\\ restriction fragment. Another deletion analysis from 5' of the
minimal enhancer could be applied to determine the 5' boundary of CD4 minimal
enhancer.
4.

Fragments within CD4 minimal enhancer

a.

A 145 bp positive fragment.

There is a 119 bp fragment (671-709) deleted in pS7 compared to pS6.
The CAT activity of pS7 drops by 57% due to this deletion. Interestingly, as the
Bal31 deletion goes 26 bp further in the 5' direction (pS8) cutting the CD4-2, the
CAT activity drops by an additional 91% and reached the lowest point of CAT
activity. The 145 bp region present in pS6 but deleted in pS8 has a positive effect
on CD4 gene expression. The 3' end of this 145 bp region is located at 372 bp 5'
of Apa\ (1162). From DNA sequence analysis, the 145 bp region contains CD4-3,
part of CD4-2 and the human homology region 8 and 9. So the human homology
region 8 and 9 may have a positive function in CD4 gene expression. The
function of CD4-2 and CD4-3 will be discussed below.
b.

CD4-2 also plays an important role in the function of CD4
minimal enhancer

Three nuclear protein binding sites (CD4-1, CD4-2 and CD4-3) within this
minimal enhancer were identified by DNase I footprint analysis (Sawada and
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Littman, 1991). Site-directed mutagenesis of these sites were also tested.
Mutation of CD4-1, CD4-2 or both of them did not significantly affect the function
of the CD4 enhancer. But, mutation of CD4-3, CD4-3 and CD4-1, or CD4-3 and
CD4-2 did decrease the function of the CD4 enhancer significantly. These data
indicate that CD4-3 is the important element for CD4 enhancer function, but that
CD4-1, or CD4-2, have only a slight effect on CD4 enhancer function. In our
studies, the deletion of CD4-3 results in a 57% reduction of CAT activity. This
result supports the idea that CD4-3 plays an important role in the function of the
CD4 enhancer. But the data also show that even when CD4-3 is deleted, the
remaining elements in the minimal enhancer can still positively stimulate the CD4
promoter. A further deletion touching on CD4-2 abolishes the entire function of
the CD4 minimal enhancer. This suggests that CD4-2 is also important for the
function of the CD4 minimal enhancer. Sawada and Littman (1991) concluded
that site-directed mutagenesis of the CD4-2 site had only a slight effect on
enhancer function in T cell lines. Careful examination of their data reveals that the
mutated CD4 regions were tested in JURKAT cells (human CD4+CD8‘) which are
different from the SAKRTLS12.1 cells used in this work. Also, their data showed
that one of the mutations of CD4-2 reduced CAT activity by about 59%.
5.

A 364 bp DNA region (1-364) has a negative effect on the CD4
promoter.

S16 is the construct containing no enhancer but only the promoter. If the
CAT activity value of a construct is significantly lower than that of S16, it indicates
the existence of a negative function. Among the CAT activity values of pS8
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through pS13, there are no significant differences. But compared with CAT value
of S16, their CAT activity values dropped between 17% (pS8) and 47% (pS10)
indicating the existence of a negative function. The CAT activity values obtained
from transfecting pS14, pS15 and pS16 are not significantly different. When S13
was further deleted corresponding to S14, the negative effects did not exist
anymore. Therefore, a 364 bp DNA fragment corresponding to S13 (1-364) has a
negative effect on the CD4 promotor, showing the function of a silencer. This
364bp DNA region contains two human homology regions (1 and 2). In addition,
the position of this 364 bp fragment having a silencer function corresponds to the
DH site 4 identified by Sands and Nikolic-Zugic (1992).
6.

Summary

The deletion analysis reported in this dissertation shows the following: 1)
the minimal enhancer is necessary for higher expression from the CD4 promoter;
2) the 3' boundary of the minimal enhancer is located 120 bp 5' of the Avail
restriction site referred to as the 3' end of the minimal enhancer; 3) the 219 bp
fragment of which the 3' end is located 153 bp upstream of Apa\ (1126) site
appears to have a neutral function in CD4 gene expression; 4) the 145 bp region
located 120 bp 5' of the Avail restriction site is necessary for the function of the
minimal enhancer; 5) a 364 bp DNA region (1-364) has a negative effect on the
CD4 promoter.
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CHAPTER FOUR
IV.

IDENTIFICATION AND CHARACTERIZATION OF THE NOVEL
SILENCER UPSTREAM OF THE CD4 ENHANCER
As described in chapter 3, a 364 bp DNA fragment corresponding to S13

(1-364) has a negative effect on the CD4 promoter, suggesting that it functions
as a silencer. This 364bp DNA region contains two human homology regions (1
and 2). To further define this 364 bp DNA fragment as a silencer, this 364 bp
fragment (named as S-a in this chapter) was first subcloned at different locations
and orientations relative to the CD4 promoter in the p900 construct (Fig. 4.1).
These constructs were then transfected into SAKRTLS12.1 (CD4+CD8 ) cells
and their CAT activities were measured. By analyzing the data from CAT
assays, it can be determined whether this 364 fragment DNA can down-regulate
the CD4 promoter at different positions and with different orientations. Finally
the interactions between S-a and the nuclear factors were identified and
characterized using EMSA and DNase I footprint techniques.
A.

Results
1.

Explanation of constructs (Fig. 4.1)

a.

The Construct p900

The p900 construct consists of the murine CD4 promoter region and
pCAT basic vector. In the p900 construct, the CD4 promoter region is located
immediately upstream of the CAT reporter gene. Therefore, the CAT reporter
gene is driven by the CD4 promoter.
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Figure 4.1. Diagrams of constructs p900, p900 control, Hind/a, Hind/b,
BamH/a, BamH/a and BamH/b. The construct p900 is the construct which
consists of the murine CD4 promoter region and pCAT basic vector. In the p900
construct, the CD4 promoter region is located immediately upstream of the CAT
reporter gene. The construct p900 control contains a 360 bp nonfunctional
fragment upstream of the CD4 promoter. The construct Hind/b contains the
DNA fragment S-a upstream of the promoter at same orientation. The construct
Hind/a contains the DNA fragment S-a upstream of the promoter but in the
opposite orientation. The construct BamH/b contains the DNA fragment S-a
downstream of the promoter in the same orientation. The construct BamH/a
contains the fragment downstream of the promoter in the opposite orientation.
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b.

The Construct Hind/a

The construct Hind/a was obtained by inserting S-a into p900 at the
H/ndlll site located upstream of the CD4 promoter region. In the construct
Hind/a the S-a fragment has an opposite orientation relative to the CD4
promoter.
c.

The Construct Hind/b

The construct Hind/b was obtained by inserting S-a into p900 at the
Hin6\\\ site located upstream of the CD4 promoter region. In the construct
Hind/b the S-a fragment has the same orientation relative to the CD4 promoter.
d.

The Construct BamH/a

The construct BamH/a was obtained by inserting S-a into p900 at the
BamH\ site located downstream of the CD4 promoter region. In the construct
BamH/a the S-a fragment has an opposite orientation relative to the CD4
promoter.
e.

The Construct BamH/b

The construct BamH/b was obtained by inserting S-a into p900 at the
BamH\ site located downstream of the CD4 promoter region. In the construct
BamH/b the S-a fragment has the same orientation relative to the CD4 promoter.
f.

The construct p900 control

The construct p900 used as a control to test whether a nonfunctional
fragment can down-regulate the function of the CD4 promoter. The construct
p900 was obtained by inserting a 360 bp nonfunctional fragment into p900 at the
HindlM site located upstream of the CD4 promoter region.
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2.

The results of CAT assays (Fig.4.2)

a.

A 360 bp nonfunctional DNA fragment did not affect the
promoter function significantly

Comparing construct p900 with p900 control, p900 contains a 360 bp
nonfunctional DNA fragment upstream the CD4 promoter, whereas p900 does
not. Comparing the CAT activities between p900 and p900 control, there is no
significant difference (p>0.05). Therefore the 360 bp nonfunctional DNA
fragment did not affect the promoter function significantly.
b.

The 364 fragment DNA can down-regulate the CD4 promoter at
different positions and with different orientations.

The p900 contains only the murine CD4 promoter located immediately
upstream of the CAT reporter gene to drive the CAT reporter gene. In contrast
the construct Hind/b and the construct Hind/a contain the S-a fragment upstream
of the promoter at same and opposite orientation relative to the CD4 promoter
respectively. Comparing the CAT activities of p900, the CAT activities of the
construct Hind/b dropped to 37% and the CAT activities of the construct Hind/a
dropped to 77%. The construct BamH/b and the construct BamH/a contain the
S-a fragment downstream of the promoter at same and opposite orientation
relative to the CD4 promoter respectively. Comparing the CAT activities of p900
the CAT activities of the construct BamH/b dropped to 52% and the CAT
activities of the construct BamH/a dropped to 61%. Therefore, this 364 bp DNA
fragment (S-a) down-regulated the CD4 promoter at different positions with
different orientations.

127

CD
0
-C

£*
0

o sz
=3 I-

iz

.

c
o
o

C\J

0

CO

0
JZ

I-

or

o

0 <

0 .— -3

8? -O LU
O ■§ w
o o +|
0
0 c
X c 0
0
0

0

x i= ^

000
^ O 0
. CD
O CL £I
0

S c 0
a ® £

o

"a

CL
0

0 0^

£ c 3
0
^

±;
3

0
X)

0

c:

21

0

S. ° s?
Egg
o

O ^
>, 0)

~

CD
0

^ 0

^

0^0

< o ~
^ 0 o
, o

<<g.
°O
0 0 o
^ CD 0

B
S c c 0
0

0

>

0

0

>

0
’ .c

^
0

O
p
>,
^
S—
-t—'
Q. Q-5

^
®
3
D)

H

0 <
0 O
‘X 0
0 _C

il X ~
128

-Q

X

E
Cti
m

X

E

«3

CO

§
.£
X

J2
u

s
§
o
=5
.5
X

2
o
o

<g^

o

CJ

o

o
oo

o

<o

o

o

CM

006d io juaojad Aiiaipv XVO

129

o

3.

Results of the electrophoretic mobility shift assay (EMSA)

EMSA is a powerful method for analysis of DNA-nuclear protein
interactions. The interactions between the functional DNA fragment (S-a) and
individual nuclear extract from SAKRTLS12.1, TB2.1 and AKR1.G.1 were
identified by EMSA, and the specificity of the interactions was determined by the
competition assay. In figure 4.3, the 5' end labeled S-a (called probe in this
case) alone was loaded on lane 1. The probe with nuclear proteins from
SAKRTLS12.1 cells was loaded on lanes 2 to 4. From lane 2 to lane 4 the
concentrations of nuclear protein were from low to high. The probe with nuclear
proteins from TB 2.1 cells was loaded on lanes 5 to 7. The probe with nuclear
proteins from AKR cells was loaded on lanes 8 and 9. The positions of the
protein/DNA binding complex were indicated with arrows. EMSA shows that the
sizes of protein/DNA binding complexes are the same among the three individual
cell lines.
4.

Results from competitive mobility gel shift assay

Competitive mobility gel shift assays were performed to further confirm
that the formation of the bands in EMSA are due to specific binding between the
nuclear proteins and the DNA probe. In the figure 4.4 the probe ( p32 labeled Sa) alone was loaded on lane 1. The probe and nuclear factors extracted from
SAKRTLS12.1 cells were loaded on lane 2. The same nuclear factors and the
probe competed with unlabeled S-a from low concentration to high concentration
(50 to 200 fold excess) were loaded on lane 3 to 6.
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The nuclear factors extracted from SAKRTLS12.1 cells and the probe competed
with a non-specific DNA fragment (200 fold excess) were loaded on lane 8. The
positions of the protein/DNA binding complexes were indicated with an arrow.
The competitive EMSA shows that as the concentration of competitive DNA was
increased the density of band decreased and finally disappeared. Even though
the concentration of the non-specific DNA fragment was very high relative to the
probe (200 fold excess), the density of the band decreased very little. Therefore
the formation of these bands are due to the binding between the nuclear proteins
and the DNA probe.
EMSA and competitive EMSA show the existence of specific binding of
nuclear factors to this 364 bp silencer.
5.

Four nuclear protein binding sites were identified within the
364 bp DNA fragment (S-a) by the DNase I footprint technique.

DNase I footprint is a technique to study the sequence-specific binding of
protein to DNA. This technique can be used to determine the site to which the
sequence-specific DNA-binding proteins bind and has been extensively applied
to the study of transcription factors. To determine which transcriptional factors
could be responsible for the silencer function of S-a, the DNase I footprint
analysis on S-a was performed using crude nuclear extracts from SAKRTLS12.1
cells. Four discrete regions (FP1 to FP4) within S-a were protected from the
DNase I digestion (Figure 4.5).
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Figure 4.5. DNase I footprinting analysis of nuclear protein binding sites
within the DNA fragment S-a. DNase I digestion of the probes in the absence
of nuclear extracts is shown in the lanes 2 and 3; DNase I digestion of the
probes incubated with nuclear extracts purified from SAKRTLS12.1 T cell line is
shown in the lanes 4, 5, and 6. The group A represents 5' end-labeled S-a
probe; the group B represents 3' end-labeled S-a probe. Footprinted regions
are indicated by vertical lines and are labeled FP1 to FP4. Mapping of the
DNase I footprinted regions was determined by DNA sequencing ladder (G+A)
generated by piperidine cleavage of a formic acid-treated probe. DNA
sequencing ladders (G+A) were shown in lanes 1 and 6.
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FP4

DNase I digestion of the probes in the absence of nuclear extracts is shown in
the lanes 2 and 3; DNase I digestion of the probes incubated with nuclear
extracts purified from SAKRTLS12.1 T cell line is shown in the lanes 4, 5, and 6.
The group A represents 5' end-labeled S-a probe; the group B represents 3'
end-labeled S-a probe. Footprinted regions are indicated by vertical lines and
are labeled FP1 to FP4. Mapping of the DNase I footprinted regions was
determined by a DNA sequencing ladder (G+A) generated by piperidine
cleavage of a formic acid-treated probe. DNA sequencing ladders (G+A) were
shown in lanes 1 and 6.
6.

Sequence analysis of footprinted regions

Nucleotide sequences of the footprinted regions within S-a are shown in
figure 4.6. Regions double underlined are the footprinted regions 1-4 (FP1, FP2
FP3 and FP4) that bind to frans-acting factors. DNA sequences of the
footprinted regions were further analyzed using the TRANSFAC database 4.0
program. Several potential binding sites for transcriptional factors were found
within these footprinted DNA regions. Footprinted region 1 (FP1) encompasses
potential binding sites for a basic helix-loop-helix (bHLH) protein E12/E47
(CANNTG), the nuclear factor I (NF-1), and LEF-1 (CANAG); footprinted region 2
(FP2) encompasses a potential binding site for ADD1 (NATCACGTGAY);
footprinted region 3 (FP3) encompasses a potential binding site for GR
(TGTGAT); and footprinted region 4 (FP4) encompasses potential binding sites
for c/EBP a (GAGGAGGG) or Sp1 (GCCCCCTCCCC).
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Figure 4.6. Nucleotide sequence of the footprinted regions. Nucleotide
sequence of the footprinted regions within S-a are shown. Regions double
underlined are the footprinted regions 1-4 (FP1, FP2, FP3 and FP4) that bind to
frans-acting factors.
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1

GGCCGCAAGG GTTGAGGAAT TGTCTCTGA ACAGGCTCGC

41

TCACTTGGTC GAGGGCCAGAG GCCTCAGTT CTTCCTCTTT
FP-1

81

AGTGCCATGG CAACTGGCCT CTCTGTGGAC AGGATGGATG

121

AGACAAAAGC ACTCAGGCGT CATCACCT GA TCTTGAAAGT
FP-2

161

GATAGGTCAT CATTT CTGCC CCT GTCTGTA GATCACACAG
FP-3

201

G CCA CTTGTG ACACGGTATA GGAAATGCAA GATAAGGATG

241

TCAACCAAGG AAGGGGATTG CT GGGACCTC TTAGAGCCTG

281

GCTGTCACA A GCTAGCAGTA CTTGAATGAC AGACAGCCCA

321

AG AAAGAGGA GGGGGCATC T CTGATTATCC GACATCTGTG
FP-4

361

CCC
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B.

Summary
The results from transient transfection and CAT assays show that the 364

bp DNA fragment can down-regulate the CD4 promoter at different positions and
with different orientations. EMSA and competitive EMSA show the existence of
specific binding of nuclear factors to this 364 bp DNA fragment. Furthermore
four nuclear protein binding sites were identified within the 364 bp DNA fragment
by the DNase I footprint technique. Sequence analysis shows that these
footprinted DNA regions contain several potential binding sites for transcriptional
factors such as: basic helix-loop-helix (bHLH) protein E12/E47, nuclear factor I
(NF-1), LEF-1, ADD1, c/EBP a and Sp1. These results are consistent with
identification of this 364 bp DNA fragment in which the 5' end is located at Sma\
site as a CD4 silencer.
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CHAPTER FIVE
IV.

ANALYSIS OF THE CD4 ENHANCER REGION FROM THE 5

DELETION SERIES

A.

Explanation of constructs (Fig. 5.1)
1.

pAC4d

Plasmid AC4d (pAC4d) consists of 6 fragments: a) a 3477 bp Not\-Sal\
fragment, (1-3477), which contains the CD4 minimal enhancer; b) a 3714 bp
Sal\-Xho\ fragment, (3477-7191), which contains the CD4 promoter and 71 bp of
the first exon of the CD4 gene; c) a 612 bp Xho\-Pst\ fragment, (7191-7803)
which contains the most 5' region of the first intron of the CD4 gene including the
splice donor sequences; d) a 175 bp Pst\-Sal\ fragment, (7803-7978), which
contains 175 bp of the most 3' region of the first intron of the CD4 gene
including the splice acceptor sequence); e) a 1655 bp Sal\-Asc\ fragment, (79789633), which contains the CAT gene of pCAT Basic (Promega, Madison, Wl); f)
a 3165 bp Asc\-No1\ fragment, (9633-12798), containing the ampicillin resistance
(AmpR) and the origin of replication of pSL1180 (Pharmacia Biotech Inc.
Piscataway, NJ).
2.

Bal31 deletion series (Fig. 5.1)

The deletion series was obtained by using Bal31 nuclease to delete DNA
sequences between a Sma\ site, positioned 5' of the Apa\ site at 2078 in pAC4d
and an Apa\ site, positioned at 3236 in pAC4d. The Bal31 deletions all start from
the Sma\ site and stop at different points 3' of the Sma\ I site.
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Figure 5.1. Composition of constructs pAC4d, pS’18 and Bal 31 deletion
series.
pAC4d consists of 6 fragments: a) a 3477 bp Not\-Sal\ fragment, (1-3477),
which contains the CD4 minimal enhancer; b) a 3714 bp Sal\-Xho\ fragment,
(3477-7191), which contains the CD4 promoter and 71 bp of the first exon of the
CD4 gene; c) a 612 bp Xho\-Pst\ fragment, (7191-7803), which contains the
most 5' region of the first intron of the CD4 gene including the splice donor
sequences; d) a 175 bp Pst\-Sal\ fragment, (7803-7978), which contains 175 bp
of the most 3' region of the first intron of the CD4 gene, including the splice
acceptor sequence); e) a 1655 bp Sal\-Asc\ fragment, (7978-9633), which
contains the CAT gene of pCAT Basic (Promega, Madison, Wl); f) a 3165 bp
Asc\-Not\ fragment, (9633-12798), containing the ampicillin resistance (AmpR)
and the origin of replication of pSL1180. pS’18 is a deletion product of pAC4d.
pS’18 does not contain a 6348 bp Not\-Bcl\ fragment, (1-6348). pS’18 does not
contain the CD4 enhancer, but does contain the CD4 promoter. The Bal31
deletions (pS’1-pS’17) all start from the Sma\ site and stop at different points 3'
of the Sma\ I site. Each deletion construct contains the pAC4d sequences
between 6348 bp and 12,798 bp, but does not contain the two fragments present
in pAC4d. These two fragments are: a 2078 bp fragment Not\-Sma\ (1-2078)
and a 3112 bp fragment Apa\-Bcl\ (3236-6348). Among the deletion series the
DNA 5‘ of each deletion end is identical. The number following each plasmid
construct indicates the location of the end point of the Bal31 deletion in that
construct. For example, S’2-26 means that the end point of the Bal31 deletion in
pS2 is at 26 bp 3' of the Sma\ site.
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All the Bal31 deletions are fused at a blunted A/ofl site in such a way to make the
5' region of each deletion construct identical, each containing the pAC4d
sequences between 6348 bp and 12,798 bp. Each deletion construct, pS1 to
pS17, does not contain a 3112 bp Apa\-Bcl\ fragment (3236-6348) that is present
in pAC4d. The number following each plasmid construct indicates the location
of the end point of the Bal31 deletion in that construct. For example, S’2-26
means that the end point of the Bal31 deletion in pS2 is at 26 bp 3' of the Sma\
site. Among the deletion series the DNA 5' of each deletion is identical.
3.

Plasmid S’18 (pS’18)

pS’18 is a deletion product of pAC4d. pS’18 does not contain a 6348 bp
Not\-Bcl\ fragment, (1-6348). pS’18 does not contain the CD4 enhancer, but
does contain the CD4 promoter. The size of pS16 is 6,450 bp. pS’18is
identical to pS16 which was used in 3' deletion series.

B.

Relative positions of deletion ends compared to CD4 minimum
enhancer, CD4-1, CD4-2, CD4-3 and human homology region.
The murine CD4 minimal enhancer is a 339 bp fragment (Sawada and

Littman, 1991). Within this minimal enhancer, three protein binding regions
were defined and named CD4-1, CD4-2 and CD4-3 (Sawada et al., 1995).
There are 11 regions within the 1166 bp fragment 51 of the Apa\ site,
positioned at 3236 in pAC4d, that have homology to the human CD4 enhancer
(Hansen, 1995; Blum et al., 1993) (Fig. 5.2 and Fig. 5.3). Four of these
homologous regions, regions 1-4, are located 5' of murine CD4 minimal
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enhancer. All the positions shown in figure 5.2 are relative to the position 9
corresponding to the Sma\ site found in pAC4d at nucleotide 2078. Position 1-8
is a Not\ site. Region 1 (149-204) has 75% homology. Region 2 (263-289) has
81% homology. Region 3 (381-431) has 71% homology. Region 4 (500-528)
has 69% homology. Six of the regions having homology to the human enhancer,
regions 5-10, are located within the murine CD4 minimal enhancer. Region 5
(550-581) has 66% homology. Region 6 (587-608) has 91% homology. Region
7 (612-638) has 74% homology. Region 8 (694-721) has 72% homology.
Region 9 (729-765) has 86% homology. Region 10 (769-813) has 83%
homology. The last region of sequence homology, region 11 (918-943), is 3' of
the CD4 minimal enhancer and has 75% homology.
C.

Results from CAT assays
1.

A 252 bp fragment immediately downstream of the Smal site
can down regulate CAT expression when the CD4 enhancer is
located adjacent to the CD4 promoter.

The CAT activities obtained from transfecting S’5, S’6, S’7 and S’8 are not
significantly different and they are about 5.5 fold higher than that of S’18. When
a 252 bp fragment corresponding the DNA fragment between the deletion end
points of S’1 and S’5 was deleted, the CAT activity increased 59%. Therefore
this 252 bp fragment has a negative effect on the CD4 promoter even in the
presence of the CD4 enhancer.
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Figure 5.2. DNA sequence from the A/ofl site (1) to the Sa/I site (1409). The
sequence region underlined is the murine CD4 minimal enhancer. Red color
sequence regions represent human homology regions (Hhr). Regions double
underlined are the murine CD4 regions 1-3 (CD4-1, CD4-2, CD4-3) that bind to
frans-acting factors. The arrows indicate the location of the end of the Bal31
deletion in each construct.
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▼S’1
TS2
1 GGCCGCAAGG GTTGAGGAAT TGTCTCTGA ACAGGCTCGC
41 TCACTTGGTC GAGGGCCAGA GGCCTCAGTT CTTCCTCTTT

81 AGTGCCATGG CAACTGGCCT CTCTGTGGAC AGGATGGATG
▼S’3
121 AGACAAAAGC ACTCAGGCGT CATCACCT GA TCTTGAAAGT
▼S’4
161 GATAGGTCAT CATTTCTGCC CCTGTCTGTA GATCACACAG
Hhr1
201 G C CA CTT GT G AGACGGTATA GGAAATGCAA GAT AAGGAT G
▼S’5
241 TCAACCAAGG AAGGGGATTG CT GGGACCTC TTAGAGCCTG
Hhr2
281 GCTGTCACA A GCTAGCAGTA CTTGAATGAC AGACAGCGCA
▼S’6
321 AGAAAGAGGA GGGGGCATCT CTGATTATCC GACATCTGTG
361 GCCTTCTCAG GGAATTGGCA GG CTCCTCCA CTGTCAACTT
▼S7
401 TGCAGAAGTT CTGGAGGCTA ATCAAGGCCAA TCCTGCAGG
Hhr3
441 TAGAAGGCTA CCCGGTGGAC CTCCAGACCC TTGGCTACTG
▼S’S

481 CTCCTTCCAC ATATGAACT T GTTTACAGGG CTTCATGGCT
Hhr4
521 CAGAACCT AC GCAGAGAATT TTCTGTTCT A CATCCCCAAC
Hhr5
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▼S’9
▼S’lO
561 CAAGCCA AGGTGTTGGGGTTC AAATT T GAG CCCCAGCTGT
Hhr6
661 TAGCCCT CTGC AAAG AAAAA AAAAAAAAAA AAAGAACA AG
CP4-1
Hhr7
TS’11
641 GGGCCTAGATT TCCCTTCTG AGCCCCACCC TAAGATGAAG
CD4-2
661 CCTCTTCTTT CAA GGGAGTG GGGTTGGGGTGGAGGCGGAT
Hhr8
▼S’12
721 C CTGTCAG CT TTGCTCTCTC TGTGGCTGGC AGTTTCTCCA
Hhr9
TS’13
▼S’14
761 AAGGG TAA CAGGTGTCAGCT GGCTGAGCCT AGCTGAACCC
CP4-3
HhiiO
▼S’15
801 TGAGACATGC TAG CTCTGTC TTCTCATGGC TGGAGGCAGC

841 CTTTGTAAGT CACAGAAAGT AGCTGAGGGG CTCTGGAAAA
881 AAGACAGCGA GGGTGGAGGTAGATTGGTCC TTCTAGT TGC
921 AGCTTCCAAG GTGCCGCCAGGGT CTGGGCGTTTCACCCCA
Hhr11
▼S’16
961 CACCAAGGAG AAGCCTTTGT AACCCAGCCC AGCTACCGAC
1001 CCAAGCCCAC CCCACAGCTA TTTTGCGGGA GTTTCAGTGC
1041 TATAGCAGAT GGTTTCTGTA ACGAGTCACC ACAGGCTGCA
▼S’ 17
1081 CCTGGTGCTC CACTTCCATC GTC CTCATCT CTAATACACT
1121 GGCCTCCTCT AGTGCTCTTT TGGCAGCCTC TCACAGTGTC
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V$’f8/Apal(1162)
1161 CGGGCCCCTG CTTCCTTTCT CCCATTTGGT CACCTTCCCC
1201 TCTTCTAGCT AGAAGCACAG AATATGGACA GCAAACATAG
1241 CTCCAAACAA GAACTAGGAA TCTGCAAAAA TCAGGCTCTA

1281 AGCTCACCTT CAGGGACCGG GGCAGACAGC CTGACTTCAG
1321 TTTCCTTTGT AAAATGAGGA TAGCGAGCTG ACCTCGGTGG

1361 CTCTTGCCTG TAGCCTTCCA ACTCGGAGGC TGAGGCAGGA
W Sail(1409)
1401 AGAGCTGGTC GACCAGCTCA
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Figure 5.3. Relative positions of the deletion ends compared with the
locations of CD4 enhancer binding element, CD4-1, CD4-2, CD4-3, and the
11 human homology regions. The position of the minimal murine CD4
enhancer (mCD4enh), the protein binding sites, CD4-1, CD4-2, CD4-3, present
within the mCD4enh (CD4r), and the 11 regions that show homology to the
human enhancer (Hhr) are shown as gray boxes beneath the plasmid pS1. The
DNA present in the pS’1 to pS’17 Bal31 nuclease deletion constructs are show
below the human homology regions. The number following each deletion
construct indicates the location of the Bal31 deletion end point in that construct.
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2.

A 230 bp fragment 256 bp downstream of Sn?al site has a
neutral function in the presence of the CD4 enhancer.

The CAT activities obtained from transfecting pS’5, pS’6, pS7 and pS’8
into SAKRTLS12.1 are not significantly different. This indicates that the 230 bp
of DNA between the deletion end of S’5 and S’8 does not affect the ability of the
CD4 promoter to express the CAT report gene in the presence of CD4 enhancer.
Therefore, this 230 bp region appears to have a neutral function relative to its
ability to stimulate or repress the CD4 promoter in the presence of the CD4
enhancer.
3.

A 237 bp fragment 486 bp downstream of the Sma\ site
containing human homology regions 4 to 8, is essential for the
function of the CD4 enhancer.

The CAT activity of S’8 is 5.5 fold higher than that of S’18 which contains
the CD4 prmoter but no CD4 enhancer, indicating the presence of an enhancer.
As the deletion goes further along the downstream direction, the CAT activities
drop. When a 237 bp DNA fragment, from the deletion end of S’8 to S’12, is
deleted corresponding to the deletion end of S’12, the CAT activity drops even
below that of S’18, indicating the loss of enhancer function. Therefore the
presence of this 237 bp fragment 486 bp downstream of the Sma\ site
containing human homology regions 4 to 8, appears to be essential for the
function of CD4 enhancer.
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4.

A 237 bp fragment 723 bp downstream of the Sma\ site
containing the human homology regions 9 and 10 has a
silencer function.

As described before, S’18 is the construct containing the promoter but no
enhancer. If the CAT activity is lower than that of S18, it indicates the existence
of a silencer function. The CAT activity values obtained from transfecting S’12
through S’15 are between 11% (S’12) and 47% (S’14) of the CAT activity value
obtained by transfecting S’18. These indicate the existence of a silencer
function in each of these constructs. Among the CAT activities of S’16, S’17 and
S’18, there is no significant difference. However, when a 237 bp fragment
containing DNA fragment between the deletion end-points of S’12 and S’16 was
deleted corresponding to S16, the silencer function no longer existed.
Therefore, this 237 bp fragment which locates 723 bp downstream of the Sma\
site and contains the human homology regions 9,10 and 11 has a silencer
function.
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CHAPTER SIX
VI.

IDENTIFICATION AND CHARACTERIZATION OF THE NOVEL
SILENCER DOMNSTREAM OF THE CD4 ENHANCER

As described in chapter 5, a 237 bp fragment 723 bp downstream of the
Sma\ site has a negative effect on the CD4 promoter, showing the function of a
silencer. This 237 bp DNA region contains two human homology regions (9 and
10). To further define this 237 bp DNA fragment as a silencer, a 292 bp DNA
fragment containing this 237 bp DNA fragment was obtained by BamH\/Not\
double digestion of the construct S3 (S3 is the construct made by 3' deletion)
followed by gel purification. This 292 bp DNA fragment (named as S-b) was first
subcloned at different locations and orientations relative to the CD4 promoter in
the p900 construct (Fig. 6.1). These constructs were then transfected into
SAKRTLS12.1 (CD4+CD8 ) cells and their CAT activities were measured. By
analyzing the data from CAT assays, it can be determined whether this 292 bp
fragment DNA can down-regulate the CD4 promoter at different positions and
with different orientations.

Finally the interactions between S-b and the nuclear

factors were identified and characterized using EMSA and DNase I footprint
technique.
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Figure 6.1. Diagrams of constructs p900, Hind/a, Hind/b, BamH/a, BamH/a
and BamH/b. The construct p900 consists of the murine CD4 promoter region
and pCAT basic vector. The CD4 promoter region is located immediately
upstream of the CAT reporter gene. The construct Hind/b contains the DNA
fragment S-b upstream of the promoter at same orientation. The construct
Hind/a contains the DNA fragment S-b upstream of the promoter but at opposite
orientation. The construct BamH/b contained the DNA fragment S-b
downstream of he promoter at same orientation. Whereas, the construct
BamH/a contained the fragment downstream of he promoter at opposite
orientation.
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A.

Results

1.

Explanation of constructs (Fig. 6.1)

a.

The Construct p900

The p900 is the construct which consists of the murine CD4 promoter
region and the pCAT basic vector. In the p900 construct, the CD4 promoter
region is located immediately upstream of the CAT reporter gene. Therefore, the
CAT reporter gene is driven by the CD4 promoter.
b.

The Construct Hind/a

The construct Hind/a was obtained by inserting S-b into p900 at the
H/ndlll site located upstream of the CD4 promoter region. In the construct
Hind/a the S-b fragment has an opposite orientation relative to the CD4
promoter.

c.

The Construct Hind/b

The construct Hind/b was obtained by inserting S-b into p900 at the
H/ndlll site located upstream of the CD4 promoter region. In the construct
Hind/b the S-b fragment has the same orientation relative to the CD4 promoter.
d.

The Construct BamH/a

The construct BamH/a was obtained by inserting S-b into p900 at the
BamH\ site located downstream of the CD4 promoter region. In the construct
BamH/a the S-b fragment has an opposite orientation relative to the CD4
promoter.
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e.

The Construct BamH/b

The construct BamH/b was obtained by inserting S-b into p900 at the
BamH\ site located downstream of the CD4 promoter region. In the construct
BamH/b the S-b fragment has the same orientation relative to the CD4 promoter.
2.

The 292 fragment DNA can down-regulate the CD4 promoter at
different positions and with different orientations (Fig.6.2).

The p900 contains only the murine CD4 promoter located immediately
upstream of the CAT reporter gene to drive the CAT reporter gene. In contrast,
the construct Hind/b and the construct Hind/a contain the S-b fragment upstream
of the promoter at same and opposite orientation relative to the CD4 promoter
respectively. Comparing with the CAT activities of p900, the CAT activities of the
construct Hind/b dropped to 60% and the CAT activities of the construct Hind/a
dropped to 72%. The construct BamH/b and the construct BamH/a contain the
S-b fragment downstream of the promoter at same and opposite orientation
relative to the CD4 promoter respectively. Comparing with the CAT activities of
p900, the CAT activities of the construct BamH/b dropped to 46% and the CAT
activities of the construct BamH/a dropped to 55%. Therefore, this 292 bp DNA
fragment (S-b) down-regulates the CD4 promoter at different positions with
different orientations.
3.

Results of electrophoretic mobility shift assay (EMSA)

The interactions between the functional DNA fragment (S-b) and
individual nuclear extract from SAKRTLS12.1, TB2.1 and AKR1 .G.1 were
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identified by EMSA, and the specificity of the interactions was determined by the
competition assay. In figure 6.3, the 5' ends labeled S-b (called probe in this
case) alone was loaded on lane 1. The probe with nuclear proteins from AKR
cells were loaded on lane 2 and 3. The probe with nuclear proteins from TB 2.1
cells were loaded on lane 4. The probe with nuclear proteins from SAKRTLS12.1
cells were loaded on lane 5. The positions of protein/DNA binding complex were
indicated with arrows. EMSA shows that the sizes of protein/DNA binding
complexes are different among the three individual cell lines.
4.

Results from competitive mobility gel shift assay

The competitive mobility gel shift assays were performed to further
confirm that the formation of the bands in EMSA are due to the binding between
the nuclear proteins and the DNA probe (Fig. 6.4). The probe ( p32 labeled S-b)
alone was loaded on lane 1. The probe and nuclear factors extracted from
SAKRTLS12.1 cells were loaded on lane 2. The same nuclear factors and the
same amount of probe competed with unlabeled S-b from low concentration to
high concentration (50 to 200 fold excess) were loaded on lane 3 to 6. The
nuclear factors extracted from SAKRTLS12.1 cells and the probe in competition
with a non-specific DNA fragment (200 fold excess) were loaded on lane 8. The
positions of the protein/DNA binding complexes were indicated with arrows. The
competitive EMSA shows that as the concentration of competitive DNA gets
higher the density of band decreased and finally disappeared. Even though the
concentration of the non-specific DNA fragment was very high relative to the
probe (200 fold excess), the density of the band almost decreased very little.

166

0

c

CD

c

< £ o c -§
? I- -O 0
Q

c .-gsg
5“ CN
0

0

CL O

— m
0
0 i—
2^000
0 O:
JZ ^
1— <

S^ ^
>
0
C

=3 ^
C =
r- 0

S O| °

S E

0 CM

^ ^ ^ o co

8 kjd

^

to

-- 0 S

Z
Q
JD

0
i_
_

<
c
CO
0 00

> ^

CO O
TO
0

x:

C

l-o
2 5
Q. CD
CM

■Q

0 ^

^

ro -o S
X

> — c

l"5
^ -o°
S-.E CO

E

o
4=

0
O

0
0 JZ
£= .ti

2
"E
CL 0
l_

0

CJ3 .9

0 0 TJ
O C

E

° C 0 'S

° s I § SZiff0
D) _q JO —
0 0

~ CO
TJ _

0

^

3

X
0

il? 5

jQ —
CL

2
Q

0
JZ

0
< JO

_E10 o
0^ Q:

0
Q.
0
■C
O
w
._

w

-TO

0^
- 0

0

0

2
E
CL O
o

O)

c

-Q

.^

'^1- c

0
^ 4= c
_CD
£LU 0
c>, .E c
0 JD 0 O
>"O O "O
^ 0 q. 0
0M= ,
-O

^C

m
CD
CD o

-O 0

0) —

<

Z
Q
c
0

-♦—»

2

Cl

J50-OO0 O
0
0
E0 C ^ c
< ^2 0 JZ ^ g
(0
X^
0

S 2^ ^ 0 o
UJQ.^1 O cl
0
oi_ (^j JZ
c^i
o
<0

O

£
oil 1
E

S ro

Q.

H E

LO
0

. o c
0
Jr

167

Figure 6.4. Results from competitive gel shift assay. The probe ( p32 labeled
S-b) alone was loaded on lane 1. The probe and nuclear factors extracted from
SAKRTLS12.1 cells were loaded on lane 2. The same nuclear factors and the
probe competed with unlabeled S-b from low concentration to high concentration
(50 to 200 fold excess) were loaded on lane 3 to 6. The nuclear factors
extracted from SAKRTLS12.1 cells and the probe competed with a non-specific
DNA fragment (200 fold excess) were loaded on lane 8. The positions of the
protein/DNA binding complexes were indicated with arrow.
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This indicates that the formation of these bands is due to the binding between
the nuclear proteins and the DNA probe.
EMSA and competitive EMSA show specific binding of nuclear factors to
this 292 bp DNA fragment.
5.

Two nuclear protein binding sites are identified within the 292
bp DNA fragment (S-b) by the DNase I footprint technique.

To determine which transcriptional factors could be responsible for the
silencer function of S-b, the DNase I footprint analysis on S-b was performed
using crude nuclear extracts from SAKRTLS12.1 cells. Two discrete regions
(FP1 and FP2) within S-b were protected from the DNase I digestion (Figure
6.5). DNase I digestion of the probes in the absence of nuclear extracts is
shown in the lanes 2 and 3; DNase I digestion of the probes incubated with
nuclear extracts purified from SAKRTLS12.1 T cell line is shown in the lanes 4
5, and 6. The group A represents 5' end-labeled S-b probe; the group B
represents 3' end-labeled S-b probe. Footprinted regions are indicated by
vertical lines and are labeled FP1 and FP2. Mapping of the DNase I footprinted
regions was determined by a DNA sequencing ladder (G+A) generated by
piperidine cleavage of a formic acid-treated probe. DNA sequencing ladders
(G+A) were shown in lanes 1 and 6.
6.

Sequence analysis of footprinted regions

Nucleotide sequence of the footprinted regions within S-b are shown in
figure 6.6. Regions double underlined are the footprinted regions 1 and 2 (FP1
and FP2) that bind to frans-acting factors.
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Figure 6.5. DNase I footprinting analysis of nuclear protein binding sites
within the DNA fragment S-b. DNase I digestion of the probes in the absence
of nuclear extracts is shown in the lanes 2 and 3; DNase I digestion of the
probes incubated with nuclear extracts purified from SAKRTLS12.1 T cell line is
shown in the lanes 4, 5, and 6. The group A represents 51 end-labeled S-b
probe; the group B represents 31 end-labeled S-b probe. Footprinted regions
are indicated by vertical lines and are labeled FP1 and FP2. Mapping of the
DNase I footprinted regions was determined by DNA sequencing ladder (G+A)
generated by piperidine cleavage of a formic acid-treated probe. DNA
sequencing ladders (G+A) were shown in lanes 1 and 6.
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Figure 6.6. Nucleotide sequence of the footprinted regions. Nucleotide
sequence of the footprinted regions within S-b are shown. Regions double
underlined are the footprinted regions 1 and 2 (FP1 and FP2) that bind to trans
acting factors.
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1

GATCCTGTCA GCTTTGCTCT CTCTGTGGCT GGCAGTTTCT

41

CCAAAGGGTA ACAGGTGTCA GCTGGCTGAG CCTAGCTGAA

81

CCCTGAGACA TGCTACCTCT GTCTTCTCAT GGCTGG AGGC
FP-1

121

AG CCTTTGTA AGTC ACAGAA AGTAGCTGAG GGGCTCTGGA
FP-2

161

AAAAAGACAG CCAGGGTGGA GGTAGATTGG TCCTTCTAGT

201

TGCAGCTTCC AAGGTGCCGC CAGGGTCTGG GCGTTTCACC

241

CCACACCAAG GAGAAGCCTT TGTAACCCAG CCCAGCTACC

281

GAC CCAAGCCC
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DNA sequence of the footprinted regions were further analyzed using the
TRANSFAC database 4.0 program. Several potential binding sites for
transcriptional factors were found within these footprinted DNA regions.
Footprinted region 1 (FP1) encompasses potential binding sites for GR
(TCTTCT); footprinted region 2 (FP2) encompasses a potential binding site for

TCF-1a (CCTTTG).

B.

Summary
The results from transient transfection and CAT assays show that the 292

bp DNA fragment can down-regulate the CD4 promoter at different positions and
with different orientations. EMSA and competitive EMSA show the existence of
specific binding of nuclear factors to this 292 bp DNA fragment. Furthermore,
two nuclear protein binding sites were identified within the 292 bp DNA fragment
by the DNase I footprint technique. Sequence analysis shows that the
footprinted DNA regions contain potential binding sites for transcriptional factors
such as: GR, and TCF-1a. This consitent with identification of the 292 bp DNA
fragment 718 bp downstream of the Sma\ site as a CD4 silencer.
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CHAPTER SEVEN
VII. DISCUSSION AND FUTURE DIRECTIONS

A.

Complex transcriptional control of CD4 gene expression
1.

Multiple elements control the expression of CD4 gene

The development of T cells is complex. It involves cell type-specific,
stage-specific and species-specific regulation. Therefore, the CD4 gene is
regulated in a highly complex manner. There are multiple positive and negative
regulatory elements controlling the expression of the murine CD4 gene: 1) the
CD4 promoter (Siu et al.,1992); 2) the proximal enhancer (Sawada and Littman
1991); 3) the distal enhancer (Wurster er al., 1994); 4) the first intronic
enhancer(s) (Hansen, 1995); 5) the intronic silencer located 2.5 kb 3' of the
promoter (Sawada et al.,1994; Siu et al., 1994); 6) the intronic silencer located 4
kb 31 of the promoter (Hansen, 1995); 7) the 5‘ negative regions located between
the 5' enhancer and the promoter (McCready et al., 1997; Sands and NikolicZugic, 1992). However, these regulatory elements still can not fully explain the
complicated expression pattern of the CD4 gene (Littman, 1996).
2.

Two novel silencers locate beside the CD4 enhancer

The minimal enhancer plays a crucial role in the stimulation of the CD4
promoter. But the minimal enhancer may be just part of a larger control element.
In this study two novel CD4 silencers have been identified. One is a 364 bp
DNA fragment (S-a), the 5' end of which locates at Sma\ site; the other is a 292
bp DNA fragment (S-b) 718 bp downstream of the Sma\ site. These two novel
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silencers have two striking similarities with other eukaryotic silencers (Ernst and
Smale, 1995). First, each of the novel CD4 silencer functions as a transcription
inhibitor in our transient transfection studies. Second, they function in a positionand orientation-independent fashion. Unlike the intronic silencer, each of these
novel CD4 silencers has a repressive effect on the expression of the CD4 gene
particularly in the SAKRTLS12.1 cell line (CD4+CD8 ). It seems to be
contradictory to the silencer's function in down-regulating CD4 expression at
different stages of T cell development. One possible explanation is that these
silencers might participate in controlling the appropriate expression of CD4 gene
at different stages of T cell development. EMSA studies on the S-b showed that
the sizes of protein/DNA binding complexes are different among the three
individual cell lines, suggesting this silencer functions differently in various stages
of T cell development. More transient transfection studies should be performed
to understand the exact function of this silencer in various stages of T cell
development.

B.

The mechanism of silencer function
Although enhancers have been extensively described, the role of negative

regulation in gene expression is beginning to be appreciated as more examples
are described among eukaryotic gene systems. The molecular mechanisms
underlying negative regulation have been divided into four categories: 1)
competitive inhibition of enhancer factors by binding of a silencer factor to a
common sequence; 2) quenching of enhancer activity by binding of a silencer
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factor to a common sequence; 3) direct repression of the promoter complex; 4)
squelching by sequestration of transcription factors by high concentrations of
enhancer factors (Levine and Manley, 1990). Recent studies in Drosophila
suggest that repressors fall into two categories, short-range and long-range
repressors (Gray and Levine, 1996). The former permits enhancer autonomy in
modular promoters, whereas the latter functions in a dominant fashion to silence
multiple enhancers. The CD4 silencer element may directly inhibit the general
transcriptional machinery at the transcription initiation site or activators
interacting with c/s-elements located at a distance. Although the precise
molecular mechanism in which the silencer functions to drive development of
mature CDS SR T lymphocytes is unclear, recent studies showed that the Notch
pathway intermediate HES-1 binds a functional site in the CD4 silencer and
mediates silencer function (Kim and Siu, 1998). In this study, the results from
the transient transfections and CAT assays show that S-a and S-b can downregulate the CD4 promoter at different positions and with different orientations.
Therefore, the mechanism of silencers S-a and S-b could be category 3: direct
repression of the promoter complex. Data from 5' deletion series show that S-a
can down-regulate CAT expression even when the CD4 enhancer is present with
the CD4 promoter. Also in S-a the potential binding sites within the footprinted
regions seem to share common transcriptional factors with CD4 enhancer.
Therefor, the mechanism of silencer S-a might falls into category 4: squelching
by sequestration of transcription factors by high concentrations of enhancer
factors.
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C.

Potential binding sites for transcriptional factors within footprinted
DNA regions.
In S-a, footprinted region 1 encompasses potential binding sites for a

basic helix-loop-helix (bHLH) protein E12/E47 (CANNTG), the nuclear factor I
(NF-1), and LEF-1 (CANAG); footprinted region 2 encompasses a potential
binding site for ADD1 (NATCACGTGAY); footprinted region 3 encompasses a
potential binding site for GR (TGTGAT); and footprinted region 4 encompasses
potential binding sites for c/EBP a (GAGGAGGG) or Sp1 (GCCCCCTCCCC).
Among these transcriptional factors, lymphocyte enhancer-binding factor 1 (LEF1) and its closest relative, T cell factor (TCF), are high mobility group (HMG)
proteins and have been discovered as proteins binding to specific sequences in
lymphoid enhancers (Travis et al.,1991; Waterman et al., 1991). TCF-1a/LEF-1
is the lineage-specific factor binding at the CD4-2 site in the CD4 enhancer
(Sawada and Littman, 1991). TCF-1a/LEF-1 binds to DNA sequence containing
the motif S'-CANAG-S1. The E-box-binding proteins of the bHLH family, which
bind to CD4-1 and CD4-3, are involved in regulating tissue-specific transcription
of numerous genes (Sawada and Littman, 1991). ADD1 (adipocyte
determination and differentiation factor 1) is a nuclear factor of bHLH-LZ family
(Tontonoz et al., 1993) and is a potent fra/is-activator of the fatty acid synthase
(Moldes et al., 1999). GR (glucocorticoid receptor) has been demonstrated to
function co-operatively with other transcriptional factors up or down-regulating
transcription (Nishio et al., 1993; Beato et al., 1995; Gratien et al., 1998)
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In S-b, footprinted region 1 (FP1) encompasses a potential binding site for
GR (TCTTCT); footprinted region 2 (FP2) encompasses a potential binding site
for TCF-1a (CCTTTG). As mentioned above, TCF-1a/LEF-1 is the lineagespecific factor binding at the CD4-2 site in the CD4 enhancer (Sawada and
Littman, 1991). In addition, TCF is activated by signalling through the
Wnt/Wingless pathway. Recently Bienz et al (1998) proposed a model of TCF
function. In this model, a co-repressor binds to TCF in unstimulated cells
keeping the TCF enhancer inactive. In Wnt-stimulated cells, (3-catenin displaces
this co-repressor, thus allowing other enhancer-bound activators (such as
tissue-specific factors, Ets1, or signal response factors) which bind co
operatively with TCF to the Wnt-inducible enhancer to contact the basal
transcription machinery (BTM). In this model TCF functions as a transcriptional
repressor in unstimulated cells and Wnt signalling mediates relief of repression.

D.

Conclusion
The specific aims of this study were to: 1). characterize the function of the

DNA regions 3’ of the murine CD4 enhancer; 2). localize the CD4 enhancer
elements to a smaller region; 3). determine the function of the human homology
regions located 5' of the CD4 enhancer; and 4). further characterize the
functional fragments. In this study, two novel c/s-acting elements (S-a and S-b)
with silencer function were discovered by Bal 31 deletions. Their silencer
functions have been further confirmed by subcloning them at different positions
and different orientations relative to CD4 promoter. These subcloned constructs
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were tested for function in transient transfection and CAT assays. The results
show that these two c/s-acting elements (S-a and S-b) can down-regulate the
CD4 promoter at different positions and with different orientations. S-a and S-b
have also been analyzed with EMSA and competitive EMSA for their ability to
bind cell-specific nuclear proteins and the results show the existence of specific
binding of nuclear factors to S-a and S-b. In addition, the potential binding sites
for transcriptional factors within these novel c/s-acting elements have been
identified by the DNase I footprinting technique. Sequence analysis shows that
these footprinted DNA regions in S-a contain several potential binding sites for
transcriptional factors such as: basic helix-loop-helix (bHLH) protein E12/E47
nuclear factor I (NF-1), LEF-1, ADD1, c/EBP a and Sp1. Therefore, the 364 bp
DNA fragment (S-a) in which the 5' end is locates at Sma\ site is identified as a
CD4 silencer. S-a is located at the 5' of the CD4 enhancer and contains the two
human homology regions (1 and 2). Also the position of this 364 bp fragment
corresponds to the DH site 4 identified by Sands and Nikolic-Zugic (1992). In
addition, the 292 bp DNA fragment (S-b) 718 bp downstream of the Sma\ site is
identified as a CD4 silencer. Sequence analysis shows that the footprinted DNA
regions in S-b contain potential binding sites for transcriptional factors such as:
GR, and TCF-1a. S-b located at 3' of the CD4 enhancer contains the human
homology regions 9,10 and 11.
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E.

Future directions
1.

Further analysis of the transcriptional factors which bind to
these two novel silencers

Since the binding consensus sequences of transcription factors within the
silencers were localized by DNase I footprinting, mutations could be introduced
into these sites to test their binding activities using EMSA. Supershift studies
also could be performed to identify those potential transcription factors
interacting with the silencers. The further characterization of the transcription
factors could provide a better understanding of the regulation of CD4 gene
expression during T cell development.
2.

Further investigation of the roles of these two novel silencers
in tissue-specific and developmental stage-specific regulation
of CD4 gene expression

The constructs containing the CD4 promoter and the novel silencer could
be tested in the different cell lines that represent different stages of thymocyte
development and different tissues to further clarify the function of the novel
silencer in various stages of T cell development and tissue-specific gene
expression.
3.

The region between the CD4 enhancer and the promoter

The region between the CD4 enhancer and the promoter also contains
sites that are potential nuclear matrix attachment regions (MARs). These sites
need to be more carefully defined to determine which sites actually function in
this capacity. Furthermore, the sites need to be investigated to determine if they
183

bind the thymocyte-enriched Tia/SATB1 protein. We have preliminary data from
a collaboration with T. Kohwi-Shigematsu (La Jolla Cancer Research
Foundation, La Jolla, CA) indicating that the Tia/SATB1 protein may be in
different forms depending on whether CD4 is expressed or repressed. These
results suggest that this protein may play a dual rule in controlling CD4
expression. The MARs can be defined to small regions of DNA by using the
classical MAR analysis. Tia/SATB1 binding can be investigated by using purified
Tia/SATB1 in electrophoretic mobility shift assays.
4.

The region immediately 5' of the CD4 promoter fragment

Previous data from Dr. Sands’ laboratory suggests that the region immediately 5'
of the 500 bp CD4 promoter fragment has a negative effect on promoter
function. This negative effect needs to be more clearly defined. This could be
done using deletion analysis of this region. The deletions should be generated
starting at the EcoRI site located 6 kb 5' of the promoter and then progressively
removing more DNA until the minimal promoter is destroyed and no CAT activity
is discernable. These constructs could then be tested in the different cell lines
that represent different stages of thymocyte development.
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